Search

Your search keyword '"Mehmet Metin Seker"' showing total 34 results
Start Over Author "Mehmet Metin Seker"
34 results on '"Mehmet Metin Seker"'

1. The prognostic value of UHRF-1 and p53 in gastric cancer

Author

Nalan A Babacan, Hatice Reyhan Egilmez, Birsen Yücel, Parlak Ilknur, Mehmet Metin Seker, Turgut Kaçan, Aykut Bahçeci, Sener Cihan, Bülent Akinci, Berna Eriten, and Saadettin Kiliçkap

Subjects
Gastric cancer, p53 genes, prognosis, survival, UHRF-1 protein, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background/Aims: This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer. Patients and Methods: Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis. Results: The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132). Conclusion: According to this study, UHRF-1and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differantiating between gastric cancer and gastritis.

Published
2016
Full Text
View/download PDF

2. Orbital metastasis of endocervical stromal sarcoma: a rare tumor and an uncommon metastasis

Author

Mehmet Metin Seker, Ali Ugur Uslu, Hatice Ozer, Ayse Seker, Turgut Kacan, Nalan Babacan, Handan Aker, and Sahande Elagoz

Subjects
endocervical stromal sarcoma, metastasis, orbital, Medicine
Abstract

Endocervical stromal sarcoma (ECSS) is a very rare uterine sarcoma. The most common presentation is pelvic mass and vaginal bleeding. The mainstay of treatment is surgery. There is no consensus on the adjuvant treatment. Relapses are usually in the pelvic and abdominal regions. To a lesser extent, lung, liver and bone metastases may be seen. A 46-year-old woman had total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) performed due to endometrial polyp and leiomyoma. Six months after the TAH-BSO, she was admitted to the hospital with cough and hemoptysis. A thoracic mass was detected, and a biopsy was done. The diagnosis was low-grade ECSS metastasis. One week after thoracotomy, she was admitted to the hospital with loss of vision in the left eye. An orbital mass was detected with magnetic resonance imaging. Endometrial and cervical pathology preparations were reassessed and were compatible with ECSS. We performed mammography, thorax, and abdomen and cranial imaging to rule out other malignancies that may cause lung and orbital metastasis. Partial remission was achieved with systemic chemotherapy and orbital radiotherapy. Orbital metastasis may be seen in ECSS patients. Although we have less knowledge about the choice of chemotherapeutic agents, ifosfamide and doxorubicin are effective in treating ECSS.

Published
2014
Full Text
View/download PDF

3. Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Author

Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, and Serdar Turhal

Subjects
Targeted therapy, Synovial sarcoma, Leiomyosarcoma, Eortc, Cancer Research, Soft tissue sarcoma, Oncology, Metastatic soft tissue sarcoma, Pazopanib, Clinical-Trials, General Medicine, Multikinase Angiogenesis Inhibitor, European Organization
Abstract

Aim: Description of patient characteristics, effectiveness and safety in Turkish patients treated with pazopanib for metastatic soft tissue sarcoma (STS). Patients and methods: This multicenter study is based on retrospective review of hospital medical records of patients (≥ 18 years) treated with pazopanib for non-adipocytic metastatic STS at 37 Oncology clinics across Turkey. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated with further analysis of data on the three most common histological subtypes (leiomyosarcoma [LMS], undifferentiated pleomorphic sarcoma [UPS], synovial sarcoma [SS]) in the cohort. Results: Data of 552 adults (57.6% women, median age: 52 years) were analyzed. DCR and ORR were 43.1% and 30.8%, respectively. Median PFS was 6.7 months and OS was 13.8 months. For LMS, UPS and SS, median PFSs were 6.1, 5.9 and 7.53 months and median OSs were 15.03, 12.87 and 12.27 months, respectively. ECOG ≥ 2 was associated with poor PFS and OS. Liver metastasis was only a factor for progression. Second-line use of pazopanib (vs. front-line) was associated with better PFS, its use beyond third line predicted worse OS. Adverse events (AE) occurred in 82.7% of patients. Most common AEs were fatigue (58.3%) and anorexia (52.3%) which were graded as ≥ 3 in 8.2% and 7.4% of patients, respectively. Conclusion: Pazopanib is effective and well-tolerated in treatment of non-adipocytic metastatic STS. Its earlier use (at second-line), good performance status may result in better outcomes. Worldwide scientific collaborations are important to gain knowledge on rarer STS subtypes by conducting studies in larger patient populations.

Published
2023

4. Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study

Author

Sukru Ozaydin, Caglayan Geredeli, Mehmet Fatih Can, Mahmut Gumus, Özlem Nuray Sever, Abdullah Sakin, Turkan Ozturk Topcu, Abdurrahman Isikdogan, Mehmet Metin Seker, Keziban Nur Pilanci, Muhammet Ali Kaplan, Faysal Dane, Ulku Yalcintas Arslan, Timucin Cil, Nuriye Ozdemir, Mustafa Karaagac, Mehmet Bilici, Zeynep Oruc Seker, Halis Yerlikaya, Mukremin Uysal, Dogan Koca, and Asude Aksoy

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Abdominal pain, Adolescent, Turkey, Colorectal cancer, Disease, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, 030212 general & internal medicine, Family history, Young adult, Child, Aged, Aged, 80 and over, business.industry, Age Factors, Hematology, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Vomiting, Adenocarcinoma, Female, medicine.symptom, Colorectal Neoplasms, business, Rare disease
Abstract

Background: Colorectal cancer (CRC) is a rare disease amongst children and adolescents. Previous studies have reported a number of differences between children/adolescents, young adults, and adult patients with CRC. However, none of these studies compared these age groups according to their clinicopathologic and prognostic characteristics. In the current study, we compare these three age groups. Methods:A total of 173 (1.1% of 15,654 patients) young CRC patients (≤25 years) were included in the study. As a control group, 237 adult CRC patients (>25 years) were also included. Patients were divided into three age groups: child/adolescent (10–19 years), young adult (20–25 years), and adult (>25 years). Results: Statistical differences amongst the three groups in terms of gender (p = 0.446), family history (p = 0.578), symptoms of presentation (p = 0.306), and interval between initiation of symptoms and diagnosis (p = 0.710) could not be demonstrated. Whilst abdominal pain (p < 0.001) and vomiting (p = 0.002) were less common in young adults than in other groups, rectal bleeding and changes in bowel habits were relatively less common in adolescents than in other groups. Rectal localisation (p = 0.035), mucinous adenocarcinoma (p < 0.001), and a poorly differentiated histologic subtype (p < 0.001) were less common in the adult group than in other groups. The percentage of patients with metastasis and sites of metastasis (e.g., peritoneum and lung) differed between groups. The median overall survival was 32.6 months in the adolescent group, 57.8 months in the young adult group and was not reached in the adult group (p = 0.022). The median event-free survival of the adolescent, young adult, and adult groups was 29.0, 29.9, and 61.6 months, respectively (p = 0.003). Conclusions: CRC patients of different age groups present different clinicopathologic and prognostic characteristics. Clinicians should be aware of and manage the disease according to these differences.

Published
2019
Full Text
View/download PDF

5. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors

Author

Yusuf Gunaydin, Alper Sevinc, Mahmut Gumus, Hatice Odabas, Ibrahim Vedat Bayoglu, Esma Turkmen, Nurten Kandemir, Sener Cihan, Z. Urakci, Ahmet Bilici, Turkan Ozturk, Nedim Turan, Fatih Selcukbiricik, Umut Demirci, Mehmet Metin Seker, Bala Basak Oven Ustaalioglu, [Gumus, Mahmut] Istanbul Medeniyet Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Bilici, Ahmet] Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Odabas, Hatice] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Ustaalioglu, Bala Basak Oven] Haydarpasa Numune Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Kandemir, Nurten] Ankara Onkol Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Demirci, Umut] Ataturk Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- [Cihan, Sener] Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Bayoglu, Ibrahim Vedat] Izmir Ataturk Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey -- [Ozturk, Turkan] Karadeniz Univ, Fac Med, Dept Med Oncol, Trabzon, Turkey -- [Turkmen, Esma] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey -- [Urakci, Zurat] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Gunaydin, Yusuf] Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey -- [Selcukbiricik, Fatih] Koc Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- [Turan, Nedim] Malatya State Hosp, Dept Med Oncol, Malatya, Turkey -- [Sevinc, Alper] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey -- [Bilici, Ahmet] Tem Avrupa Otoyolu,Goztepe Cikisi 1, TR-34214 Istanbul, Turkey, and DEMIRCI, UMUT -- 0000-0002-4833-6721

Subjects
Adult, Male, Nephrology, Oncology, medicine.medical_specialty, Turkey, Lymphovascular invasion, Urology, medicine.medical_treatment, Nonseminomatous germ cell tumor, 030232 urology & nephrology, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, Retroperitoneal lymph node dissection, 0302 clinical medicine, Testicular cancer, Testicular Neoplasms, Recurrence, Risk Factors, Internal medicine, Testicular Cancer, medicine, Chemotherapy, Humans, Neoplasm Invasiveness, Orchiectomy, Stage (cooking), Neoplasm Staging, Retrospective Studies, Surveillance, business.industry, Neoplasms, Germ Cell and Embryonal, Prognosis, medicine.disease, Stage I, Survival Rate, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Nonseminomatous Germ Cell Tumor, Germ cell tumors, business
Abstract

WOS: 000404154000013, PubMed ID: 27812752, Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy. Methods A total of 201 patients with CS I NSGCT after orchiectomy were included. Outcomes of active surveillance and adjuvant chemotherapy were retrospectively analyzed. The prognostic significance of risk factors for survival and relapse was evaluated. Results Of the 201 patients, 110 (54.7%) received adjuvant chemotherapy, while the remaining 91 patients (45.3%) underwent surveillance. Relapses were significantly higher for patients underwent surveillance compared to adjuvant chemotherapy group (18.3 vs. 1.2%, p < 0.001). The 5-year relapse-free survival (RFS) rate for patients who were treated with adjuvant chemotherapy was significantly better than those of patients underwent surveillance (97.6 vs. 80.8%, respectively; p < 0.001). Univariate analysis showed that the presence of LVI (p = 0.01) and treatment option (p < 0.001) were prognostic factors for RFS and pT stage (p = 0.004) and invasion of rete testis (p = 0.004) and the presence of relapse (p < 0.001) were significant prognostic factors for OS. Multivariate analysis revealed that the treatment strategy was an independent prognostic factor for RFS (p < 0.001, HR 0.54). A logistic regression analysis demonstrated that treatment options (p = 0.031), embryonal carcinoma (EC) > 50% (p = 0.013) and tumor diameter (p = 0.016) were found to be independent factors for predicting relapse. Conclusion Our results indicate that adjuvant chemotherapy is associated with improved RFS compared with surveillance for CS I NSGCT patients. Moreover, the treatment strategy is an important prognostic indicator for RFS and a predictive factor for relapse. Although adjuvant chemotherapy seems to be a suitable treatment for patients with risk factors for relapse, surveillance is still preferred management option.

Published
2016
Full Text
View/download PDF

6. Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer

Author

Ersin, Ozaslan, Ulaş Serkan, Topaloglu, Mevlude, Inanc, Umut, Gokmen Erdem, Hacer, Demir, Erkan, Arpaci, Mehmet, Metin Seker, Mustafa, Karaagac, Melih, Kiziltepe, Baki, Eker, and Metin, Ozkan

Subjects
Adult, Aged, 80 and over, Male, Organoplatinum Compounds, Leucovorin, Cetuximab, Middle Aged, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Fluorouracil, Neoplasm Metastasis, Colorectal Neoplasms, Aged
Abstract

To evaluate the efficacy and adverse events with cetuximab plus FOLFOX administered as second- and third-line therapy in metastatic colorectal cancer (mCRC) patients.IPatients were administered cetuximab plus FOLFOX as second- and third-line therapy from January 2010 through October 2015. mCRC patients with wild type KRAS were alsï given irinïtecan and/ïr ïxaliplatin cïmbined with fluorïpyrimidine±bevacizumab. Tumor respïnse and survival were evaluated using RECIST and Kaplan-Meier methïd respectively.Sixty patients were included this study. Cetuximab plus FOLFOX was administered to 40 (66.7%) patients as second-line and to 20 (33.3%) as third-line therapy. The majority of the patients had a good ECOG performance status (PS) (0 or 1). Clinical benefit was partial plus stable disease and it was 75.0% for both of these two lines. The median progression free survival (PFS) was 7.1 months (95% CI=3.2-10.9) and 6.0 months (95% CI=2.4-9.6), in the second-and third-line (p=0.484). The median ïverall survival (ÏS) was 14.3 and 9.2 mïnths in secïnd-and third-line therapy respectively (p=0.071). The common toxicities were haematologic and gastrointestinal, mostly grade 1 and 2.The addition of cetuximab to FOLFOX was well-tolerated and had antitumor activity both in second- and third-line therapy in patients with mCRC.

Published
2017

7. Lung Cancer in Women: A Single Institution Experience with 50 Patients

Author

Hatice Odabas, Birsen Yücel, Ilknur Koc Olcas, Ayfer Ay Eren, Saadettin Kilickap, Mehmet Metin Seker, Nalan Akgul Babacan, and Turgut Kacan

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Turkey, Epidemiology, Anemia, Health Status, ECOG Performance Status, Kaplan-Meier Estimate, Adenocarcinoma, Small-cell carcinoma, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Stage (cooking), Lung cancer, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Univariate analysis, business.industry, Incidence (epidemiology), Smoking, Public Health, Environmental and Occupational Health, Asbestos, Middle Aged, Prognosis, medicine.disease, Small Cell Lung Carcinoma, Survival Rate, Female, business
Abstract

Background: Lung cancer is the most common cause of cancer-related death worldwide. The incidence of lung cancer is aproximately 7-8 thousand percent in Turkish women. In this study, we aimed to evaluate the clinical, pathological properties and survival data of female patients with lung cancer who were treated in our center. Materials and Methods: From 2007 to 2012, 50 women with lung cancer were enrolled. Patient data were evaluated retrospectively. Results: The median age was 61 (40-81). Forty patients (80%) were diagnosed with non small cell lung cancer (NSCLC), 10 patients (20%) were small cell carcinoma (SCC). Twelve (24%) patients were smokers and 13 of 16 non-smokers had a history of exposure to asbestos. The most common histologic subtype was adenocarcinoma (46%) and this accounted for 71% in patients with exposure to asbestos. The most common initial Eastern Cooperative Oncology Group (ECOG) performance score was 1 (24 patients, 48%) and initial stage was IV (25 patients, 50%) in the study group. During the median 15 months (1-96 months) follow up period: 1 year overall survival (OS) was 68%, 2 year overall survival was 36% and the median survival time was 19 months. According to univariate analysis, poor ECOG performance status, advanced stage, anemia and weight loss at time of diagnosis were negative prognostic factors. However, adenocarcinoma sub-type was a positive prognostic factor. Conclusions: In this study NSCLC sub-type, poor ECOG performance score, advanced stage, anemia and weight loss were prognostic factors in Turkish women with lung cancer.

Published
2014
Full Text
View/download PDF

8. Prognosis in head and neck cancer: the importance of the patient-, and treatment-related factors

Author

Birsen Yücel, Mehmet Metin Seker, Turgut Kaçan, Ebru Akkaş Atesever, Mehmet Fuat Eren, Zekiye Hasbek, and Sivas Cumhuriyet Üniversitesi

Subjects
medicine.medical_specialty, Univariate analysis, Performance status, business.industry, Head and neck cancer, TNM staging system, medicine.disease, Gastroenterology, Comorbidity, Surgery, Metastasis, Internal medicine, medicine, Mucositis, Stage (cooking), business, Genel ve Dahili Tıp
Abstract

Amaç: Bu çalışmanın amacı baş boyun kanserinde prognostik faktör olarak komorbidite, performans durumu, hemoglobin düzeyi, kilo kaybı, radyoterapiye ara verme ve mukozitin öneminin araştırılmasıdır. Yöntem: Üniversitesimizin Onkoloji Merkezine 2006 ve 2012 tarihleri arasında, baş boyun kanseri tanısı ile tedavi edilen 210 hastanın verileri incelendi. Hastaların performans durumu, hasta başvurusunda Eastern Cooperative Oncology Group (ECOG) skorlama sistemine göre değerlendirildi. Hastalık evresi 2010’da revize edilen TNM evrelemesine göre yapıldı. Bulgular: Hastalar, medyan 24 (dağılım: 1-134) ay takip edildi. Medyan 11 (dağılım: 3-96) ayda hastaların %24'ünde nüks gelişirken, medyan 15 (dağılım: 1-134) ayda %13'ünde uzak metastaz gelişti. Tüm hastalar için 3 yıllık lokal kontrol %72, 3 yıllık genel sağkalım %59, 3 yıllık hastalıksız sağkalım %53 idi. Tek değişkenli analizde hastaların lokal kontrol oranlarını performans durumu (p=0.006), kilo kaybı (p=0.002), hastalık lokalizasyonu (p=0.003), evre (p, Objective: To investigate the importance of comorbidity, performance status, hemoglobin level, weight loss, interruption of radiotherapy, and mucositis as prognostic factors in head and neck cancer patients. Methods: Two-hundred and ten patients who were admitted to the Oncology Center of our university between 2006 and 2012, and treated for head and neck cancer were included in the study. Performance status at admission was evaluated according to Eastern Cooperative Oncology Group (ECOG) scoring system. Staging of the disease was based on TNM staging system revised in 2010. Results: The median follow-up period was 24 (range: 1-134) months. Recurrence was observed in 24% of the patients in a median 11 (range: 3-96) months. Metastasis was observed in 13% of patients, in the median 15 (range: 1-134 months). The 3-year local control, overall survival and disease-free survival rates were 72%, 59%, and 53%, respectively for all patients. The factors affecting the 3-year local control rates in univariate analysis were performance status (p=0.006), weight loss (p=0.002), localization (p=0.003), and stage (p

Published
2013
Full Text
View/download PDF

9. Survival Analysis and Prognostic Factors for Neuroendocrine Tumors in Turkey

Author

Mustafa Gürol Celasun, Nalan Akgul Babacan, Birsen Yücel, Zekiye Hasbek, Turgut Kacan, Mehmet Metin Seker, Mehmet Fuat Eren, Ayfer Ay Eren, Seher Bahar, [Yucel, Birsen -- Eren, Ayfer Ay -- Eren, Mehmet Fuat -- Bahar, Seher] Cumhuriyet Univ, Sch Med, Dept Radiat Oncol, Sivas, Turkey -- [Babacan, Nalan Akgul -- Kacan, Turgut -- Celasun, Mustafa Gurol -- Seker, Mehmet Metin] Cumhuriyet Univ, Sch Med, Dept Med Oncol, Sivas, Turkey -- [Hasbek, Zekiye] Cumhuriyet Univ, Sch Med, Dept Nucl Med, Sivas, Turkey, and Eren, Mehmet F -- 0000-0002-6531-978X

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Adolescent, Turkey, Epidemiology, Neuroendocrine tumors, survival, Gastroenterology, Young Adult, Internal medicine, Biomarkers, Tumor, Humans, Medicine, Stage (cooking), Child, Survival rate, Survival analysis, Aged, Neoplasm Staging, Aged, 80 and over, Univariate analysis, Performance status, biology, business.industry, Stomach, Public Health, Environmental and Occupational Health, prognostic factors, Chromogranin A, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Survival Rate, Neuroendocrine Tumors, medicine.anatomical_structure, Oncology, biology.protein, Female, business, Follow-Up Studies
Abstract

WOS: 000329829200086, PubMed ID: 24377589, Background: This study aimed to determine the demographical distribution, survival and prognostic factors for neuroendocrine tumors monitored in our clinic. Materials and Methods: Data for 52 patients who were admitted to Cumhuriyet University Medical Faculty Training Research and Practice Hospital Oncology Center between 2006 and 2012 and were diagnosed and treated for neuroendocrine tumors were investigated. Results: Of the total, 30 (58%) were females and 22 (42%) were males. The localization of the disease was gastroenteropancreatic in 29 (56%) patients and other sites in 23 (44%). The most frequently involved organ in the gastroenteropancreatic system was the stomach (n=10, 19%) and the most frequently involved organ in other regions was the lungs (n=10, 19%). No correlation was found between immunohistochemical staining for proteins such as chromogranin A, synaptophysin, and NSE and the grade of the tumor. The patients were followed-up at a median of 24 months (1-90 months). The three-year overall survival rate was 71%: 100% in stage I, 88% in stage II, 80% in stage III, and 40% in stage IV. The three-year survival rate was 78% in tumors localized in the gastroenteropancreatic region, and 54% in tumors localized in other organs. In the univariate analysis, gender, age, performance status of the patients, grade, localization, surgical treatment, and neutrophil/lymphocyte ratio (5) affected the prognosis of the patients. Conclusions: Most of the tumors were localized in the gastroenteropancreatic region, and the three-year survival rate in tumors localized in this region was better than the tumors localized in other sites. Surgical treatment was a positive independent prognostic factor, whereas Grade 3 and a neutrophil/lymphocyte ratio of > 5 were negative independent prognostic factors.

Published
2013
Full Text
View/download PDF

10. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy

Author

Cagatay Arslan, Omer Dizdar, Muhammet Fuat Özcan, Mevlana Derya Balbay, Gulnur Guler, Bahri Gok, Gokhan Pektas, Sercan Aksoy, Suayib Yalcin, Mehmet Metin Seker, Nazmiye Dincer, and Serdar Balci

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Time Factors, Urology, medicine.medical_treatment, Kaplan-Meier Estimate, Carboplatin, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Outcome Assessment, Health Care, medicine, Humans, Pathological, Aged, Proportional Hazards Models, Chemotherapy, Predictive marker, Bladder cancer, business.industry, Proportional hazards model, Hazard ratio, Middle Aged, Endonucleases, medicine.disease, Immunohistochemistry, Neoadjuvant Therapy, DNA-Binding Proteins, Urinary Bladder Neoplasms, Multivariate Analysis, Female, Cisplatin, ERCC1, business, Follow-Up Studies
Abstract

Purpose Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Prognostic role of ERCC1 expression in the neoadjuvant setting in bladder cancer has not been reported before. We evaluated the prognostic role of ERCC1 expression in bladder cancer receiving platinum-based neoadjuvant chemotherapy. Materials and methods Thirty-eight patients with muscle invasive bladder cancer who received neoadjuvant platinum-based chemotherapy were included. Clinical and histopathologic parameters along with immunohistochemical ERCC1 staining were examined and correlated with response rates and survival. Results Pathologic complete response rates were similar between patients with low and high ERCC1 expression. Median disease-free survival (DFS) was 9.3 vs. 20.5 months ( P = 0.186) and median overall survival (OS) was 9.3 vs. 26.7 months ( P = 0.058) in patients with high ERCC1 expression compared with those with low expression, respectively. In multivariate Cox regression analysis: pathological complete response (pCR) after chemotherapy (hazard ratio (HR) 0.1, 95% CI 0.012–0.842, P = 0.034) and high ERCC1 expression (HR 3.7, 95% CI 1.2–11.2, P = 0.019) were significantly associated with DFS. Patient age (>60 vs. ≤60 years) (HR 3.4, 95% CI 1.2–9.4, P = 0.018), the presence of pCR (HR 0.11, 95% CI 0.014–0.981, P = 0.048) and high ERCC expression (HR 6.1, 95 CI 1.9–19.9, P = 0.002) were significantly associated with OS. Conclusions Our results showed that high ERCC1 expression was independently associated with shorter disease-free and overall survival in patients with bladder cancer who received neoadjuvant platinum-based chemotherapy. ERCC1 may represent a potential predictive marker for platinum-based treatment in bladder cancer.

Published
2013
Full Text
View/download PDF

11. Is there diagnostic and prognostic importance of serum anti-p53 antibody level in lung cancer?

Author

Birsen Yücel, Omer Tamer Dogan, Seyit Ahmet Ertürk, Mehmet Metin Seker, Serdar Berk, Ismail Sari, Zekiye Hasbek, Yavuz Silig, Sivas Cumhuriyet Üniversitesi, and Niğde Ömer Halisdemir Üniversitesi

Subjects
Gynecology, Pathology, medicine.medical_specialty, business.industry, medicine, General Medicine, Lung cancer, medicine.disease, business, Anti-p53 Antibody, Cerrahi
Abstract

Amaç: Akciğer kanseri dünya genelinde kansere bağlı ölümlerin önde gelen nedenidir. Tanısal cihazlar ve teknolojik gelişmelere bağlı tedavi seçeneklerinde ilerlemeye rağmen, akciğer kanseri hastalarında genel mortalite oranı hala yüksektir. Akciğer kanseri hastalarında sağkalım oranları, özellikle ilerlemiş inoperabl hastalıkta, immunoterapi gibi yeni tedavi seçeneklerine rağmen düşüktür. p53, kanser hastalarının %60-70'inde mutasyona uğramaktadır ve bu nedenle son zamanlarda yapılan çalışmalar göstermektedir ki, serum anti-p53 antikorunun, over, özefagus, meme ve akciğer kanseri gibi bazı kanser türlerinin dedekte edilmesinde biyobelirteç olarak dikkate alınabilir. Bu çalışmada, akciğer kanseri hastalarında, serum anti-p53antikor düzeylerinin tanısal ve prognostik önemini araştırmayı amaçladık. Yöntem: Çalışmaya akciğer kanseri (AK) tanısı nedeniyle evreleme için 18F-FDG-PET / BT görüntüleme amacı ile bölümümüze sevk edilen hastalar, toraks BT'sinde şüpheli pulmoner nodül olup, patolojik FDG birikimi göstermeyen hastalar (NAPN= Non-avid FDG gösteren pulmoner nodül) ve sağlıklı gönüllüler dahil edildi. Serum anti-p53antikor düzeyleri tüm hastalarda ELISA yöntemi ile ölçüldü. Hastaların ortalama takip süresi 13 ay idi. Bulgular: Çalışmaya toplam 65 AK hastası (58E/7K), 47 NAPN hastası (20E/27K) ve 34 sağlıklı gönüllü (26E /8K) dahil edildi. Ortalama serum anti-p53antikor seviyeleri AK hastalarında 3.4ng/mL, NAPN hastalarında 3.77ng /mL, sağlıklı gönüllülerde 3.07 ng/ mL idi. AK hastaları ile NAPN hastaları arasında serum anti-p53antikor düzeyi için istatistiksel olarak anlamlı fark yoktu (p = 0.678). Hatta, hastalar ve sağlıklı gönüllüler arasında serum anti-p53Ab düzeyi için istatistiksel olarak anlamlı fark yoktu (p = 0.377). Hastaların iki yıllık medyan sağkalımı 14 aydı. Hastaların sağkalım hızında, serum anti-p53Ab düzeyinin > 3.4 ng/ mL veya, Objective: Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advancement in diagnostic tools and treatment options with technological developments, overall mortality rates in lung cancer patients remains high. Survival rates in lung cancer patients is low especially in advanced diseased inoperable patients in spite of new treatment options like immunotherapy. p53 is mutated in 60-70% of cancer patients and for this reason has been extensively studied recent researches suggest that serum anti-p53Ab can be considered as biomarkers to detect many types of cancers; as ovarian cancer, esophageal cancer, breast cancer and lung cancer. In this study we aimed that are there any diagnostic and prognostic importance of serum anti-p53Ab levels in lung cancer patients. Method: Patients were included who were referred to our department with the purpose of 18F-FDG-PET/CT imaging for staging due to lung cancer diagnosis (LC) and patients who were performed 18F-FDG-PET/CT for diagnosis in the cause of the suspected pulmonary nodule in thorax CT but not detected pathologic FDG accumulation (NAPN=pulmonary nodule with non-avid-FDG) and healthy volunteers. Serum anti-p53Ab levels were measured with ELISA method in the all patients. Mean follow up time of patients were 13 months. Results: A total of 65 LC patients (58M/7F), 47 patients with NAPN (20M/27F), and a total of 34 healthy volunteers (26M/8F) were included in this study. Median serum anti-p53Ab levels are 3.4ng/mL in LC patients, 3.77ng/mL in NAPN patients, 3.07ng/mL in healthy volunteers. There is no statistically significant difference for serum anti-p53Ab level between LC patients and NAPN patients (p=0.678). Moreover there is no statistically significant difference for serum anti-p53Ab level between patients and healthy volunteers (p=0.377). Two-year median survival of patients was 14 month. It has been found that there is no effect of serum anti-p53Ab level whether >3.4 or

Published
2017

12. Orbital metastasis of endocervical stromal sarcoma: a rare tumor and an uncommon metastasis

Author

Ayse Seker, Hatice Özer, Mehmet Metin Seker, Nalan Akgul Babacan, Sahande Elagoz, Handan Aker, Ali Ugur Uslu, Turgut Kaçan, and Seker, M.M., Department of Medical Oncology, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Uslu, A.U., Department of Internal Medicine, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Ozer, H., Department of Pathology, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Seker, A., Ibni Sina Public Health Care Center, Sivas, Turkey -- Kacan, T., Department of Medical Oncology, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Babacan, N., Department of Medical Oncology, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Aker, H., Department of Pathology, Medical Faculty, Cumhuriyet University, Sivas, Turkey -- Elagoz, S., Department of Pathology, Medical Faculty, Cumhuriyet University, Sivas, Turkey

Subjects
medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, lcsh:Medicine, orbital, Case Report, endocervical stromal sarcoma, Endocervical stromal sarcoma, Metastasis, Orbital, Endometrial Polyp, Medicine, metastasis, Vaginal bleeding, Thoracotomy, Ifosfamide, Uterine sarcoma, business.industry, lcsh:R, Obstetrics and Gynecology, medicine.disease, Surgery, medicine.anatomical_structure, Leiomyoma, Abdomen, medicine.symptom, business, medicine.drug
Abstract

Termedia Publishing House Ltd., Endocervical stromal sarcoma (ECSS) is a very rare uterine sarcoma. The most common presentation is pelvic mass and vaginal bleeding. The mainstay of treatment is surgery. There is no consensus on the adjuvant treatment. Relapses are usually in the pelvic and abdominal regions. To a lesser extent, lung, liver and bone metastases may be seen. A 46-year-old woman had total abdominal hysterectomy (TAH) with bilateral salpingo-oophorectomy (BSO) performed due to endometrial polyp and leiomyoma. Six months after the TAH-BSO, she was admitted to the hospital with cough and hemoptysis. A thoracic mass was detected, and a biopsy was done. The diagnosis was low-grade ECSS metastasis. One week after thoracotomy, she was admitted to the hospital with loss of vision in the left eye. An orbital mass was detected with magnetic resonance imaging. Endometrial and cervical pathology preparations were reassessed and were compatible with ECSS. We performed mammography, thorax, and abdomen and cranial imaging to rule out other malignancies that may cause lung and orbital metastasis. Partial remission was achieved with systemic chemotherapy and orbital radiotherapy. Orbital metastasis may be seen in ECSS patients. Although we have less knowledge about the choice of chemotherapeutic agents, ifosfamide and doxorubicin are effective in treating ECSS., Seker, M.M.; Department of Medical Oncology, Medical Faculty, Cumhuriyet UniversityTurkey

Published
2014

13. Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors

Author

Ahmet Bilici, Mahmut Gumus, Hatice Odabas, Nurten Kandemir, Umut Demirci, Sener Cihan, Ibrahim Vedat Bayoglu, Bala Basak Oven Ustaalioglu, Turkan Ozturk, Esma Turkmen, Zuhat Urakci, Mehmet Metin Seker, Yusuf Gunaydin, Fatih Selcukbiricik, Nedim Turan, Alper Sevinc, and Istanbul Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- Bezmialem Univ Med Oncol, Istanbul, Turkey -- Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Ankara Onkol Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- Ankara Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Sakarya Univ, Sakarya Educ & Res Hosp, Med Oncol, Sakarya, Turkey -- Haydarpasa Numune Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Karadeniz Univ, Fac Med, Dept Med Oncol, Trabzon, Turkey -- Trakya Univ, Edirne, Turkey -- Dicle Univ, Fac Med, Diyarbakir, Turkey -- Cumhuriyet Univ, Fac Med, Med Oncol Dept, Sivas, Turkey -- Gazi Univ, Dept Med Oncol, Med Fac, Ankara, Turkey -- Koc Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- Malatya State Hosp, Dept Med Oncol, Malatya, Turkey -- Gaziantep Univ, Dept Med Oncol, Fac Med, Gaziantep, Turkey

Subjects
Germ-Cell Tumors, Cancer Research, STAGE IA, Oncology, IB NON-Seminomatous
Abstract

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2016 -- Chicago, IL, WOS: 000404711500029, …, Amer Soc Clin Oncol

Published
2016

14. The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Author

Ismail Sari, Zekiye Hasbek, Birsen Yücel, Yavuz Silig, Omer Tamer Dogan, Bülent Turgut, Mehmet Metin Seker, Serdar Berk, Sivas Cumhuriyet Üniversitesi, and [Hasbek, Zekiye -- Turgut, Bulent] Cumhuriyet Univ, Fac Med, Dept Nucl Med, Sivas, Turkey -- [Dogan, Omer Tamer -- Berk, Serdar] Cumhuriyet Univ, Fac Med, Dept Chest Dis, Sivas, Turkey -- [San, Ismail -- Silig, Yavuz] Cumhuriyet Univ, Fac Med, Dept Biochem, Sivas, Turkey -- [Yucel, Birsen] Cumhuriyet Univ, Fac Med, Dept Radiat Oncol, Sivas, Turkey -- [Seker, Mehmet Metin] Turgut Ozal Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine, 0301 basic medicine, Nükleer Tıp, lcsh:R895-920, lcsh:Medicine, Standardized uptake value, positron emission tomography/computed tomography, Anti-p53 antibody, Malignancy, Radyoloji, fluorodeoxyglucose, Lesion, 03 medical and health sciences, Tıbbi Görüntüleme, 0302 clinical medicine, Parenchyma, medicine, Radiology, Nuclear Medicine and imaging, Lung cancer, Fluorodeoxyglucose, lcsh:R5-920, medicine.diagnostic_test, biology, business.industry, lcsh:R, Lung Cancer, medicine.disease, lung cancer, 030104 developmental biology, Positron emission tomography, 030220 oncology & carcinogenesis, biology.protein, Original Article, medicine.symptom, Antibody, lcsh:Medicine (General), business, Nuclear medicine, medicine.drug
Abstract

WOS: 000391387000001, PubMed ID: 27751972, Objective: Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent F-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent F-18-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN= pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers. Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p< 0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p> 0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p> 0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion., Cumhuriyet University Scientific Research Project Unit [T-597], The work was supported by grants from Cumhuriyet University Scientific Research Project Unit (T-597).

Published
2016

15. The negative prognostic impact of bone metastasis with a tumor mass

Author

Mehmet Metin Seker, Birsen Yücel, Zekiye Hasbek, Turgut Kacan, Seher Bahar, Aykut Bahceci, Bilge Öztoprak, and Mustafa Gürol Celasun

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Time Factors, Survival, Osteoclasts, Bone Neoplasms, Young Adult, Text mining, Reference Values, Spinal cord compression, Prostate, medicine, Humans, Bone metastasis with a tumor mass, Young adult, Aged, Aged, 80 and over, lcsh:R5-920, Prognostic factor, Osteoblasts, business.industry, Hazard ratio, Bone metastasis, Cancer, General Medicine, Clinical Science, Middle Aged, Prognosis, medicine.disease, Confidence interval, Tumor Burden, medicine.anatomical_structure, Female, lcsh:Medicine (General), Epidemiologic Methods, business, Spinal Cord Compression
Abstract

OBJECTIVE: Typically, bone metastasis causes osteolytic and osteoblastic lesions resulting from the interactions of tumor cells with osteoclasts and osteoblasts. In addition to these interactions, tumor tissues may grow inside bones and cause mass lesions. In the present study, we aimed to demonstrate the negative impact of a tumor mass in a large cohort of patients with bone metastatic cancer. METHODS: Data from 335 patients with bone metastases were retrospectively reviewed. For the analysis, all patients were divided into three subgroups with respect to the type of bone metastasis: osteolytic, osteoblastic, or mixed. The patients were subsequently categorized as having bone metastasis with or without a tumor mass, and statistically significant differences in median survival and 2-year overall survival were observed between these patients (the median survival and 2-year overall survival were respectively 3 months and 16% in patients with a tumor mass and 11 months and 26% in patients without a tumor mass; p

Published
2015

16. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)

Author

Emel Sezer, Mahmut Gumus, Hatice Odabas, Serkan Menekse, Banu Ozturk, Erkan Arpaci, Ali Inal, Abdurrahman Isikdogan, Kübra Aydın, Zuhat Urakci, Mehmet Metin Seker, Ilhan Hacibekiroglu, Turkan Ozturk Topcu, Emin Tamer Elkiran, Dogan Uncu, Sener Cihan, Mevlide İnanc, Suna Cokmert, Caglayan Geredeli, Yusuf Gunaydin, Hilmi Kodaz, Bala Basak Oven Ustaalioglu, Ali Suner, Mukremin Uysal, Oznur Bal, Didem Tastekin, Ozgur Tanriverdi, Ayse Ocak Duran, Mehmet Bilici, Tokat Gaziosmanpaşa Üniversitesi, MÜ, [Inal, Ali] Mersin Hosp, Dept Med Oncol, Mersin, Turkey -- [Sezer, Emel] Mersin Univ, Dept Med Oncol, Mersin, Turkey -- [Kodaz, Hilmi -- Hacibekiroglu, Ilhan] Trakya Univ, Dept Med Oncol, Edirne, Turkey -- [Odabas, Hatice -- Aydin, Kubra] Dr Lutfi Kirdar Kartal Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Tastekin, Didem] Istanbul Univ, Dept Med Oncol, Istanbul, Turkey -- [Cihan, Sener] Istanbul Univ, Okmeydani Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Gumus, Mahmut] Bezmialem Vakif Univ, Dept Med Oncol, Istanbul, Turkey -- [Ustaalioglu, Bala Basak Oven] Haydarpasa Numune Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- [Cokmert, Suna] Kent Hosp, Dept Med Oncol, Istanbul, Turkey -- [Duran, Ayse Ocak] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey -- [Inanc, Mevlide] Kayseri Numune Educ & Res Hosp, Dept Med Oncol, Kayseri, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Dept Med Oncol, Sivas, Turkey -- [Elkiran, Emin Tamer] Inonu Univ, Dept Med Oncol, Malatya, Turkey -- [Gunaydin, Yusuf] Gazi Univ, Dept Med Oncol, Ankara, Turkey -- [Uncu, Dogan] Ankara Numune Training & Res Hosp, Dept Med Oncol, Manisa, Turkey -- [Bal, Oznur] Ankara Onkol Educ & Res Hosp, Dept Med Oncol, Manisa, Turkey -- [Menekse, Serkan] Celal Bayar Univ, Dept Med Oncol, Manisa, Turkey -- [Topcu, Turkan Ozturk] Karadeniz Tech Univ, Dept Med Oncol, Trabzon, Turkey -- [Urakci, Zuhat -- Isikdogan, Abdurrahman] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey -- [Bilici, Mehmet] Ataturk Univ, Dept Med Oncol, Erzurum, Turkey -- [Geredeli, Caglayan] Konya Numune Hosp, Dept Med Oncol, Konya, Turkey -- [Arpaci, Erkan] Sakarya Univ, Dept Med Oncol, Sakarya, Turkey -- [Ozturk, Banu] Gaziosmanpasa Univ, Dept Med Oncol, Yozgat, Turkey -- [Uysal, Mukremin] Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey -- [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Dept Med Oncol, Mugla, Turkey -- [Suner, Ali] Gaziantep Univ, Dept Med Oncol, Gaziantep, Turkey, Tanriverdi, Ozgur -- 0000-0002-0598-7284, Department of Medical Oncology, Mersin Hospital, Mersin, Turkey, Department of Medical Oncology, Trakya University, Edirne, Turkey, Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey, Department of Medical Oncology, Erciyes University, Kayseri, Turkey, Department of Medical Oncology, Cumhuriyet University, Sivas, Turkey, Department of Medical Oncology, Kayseri Numune Education and Research Hospital, Kayseri, Turkey, Department of Medical Oncology, Inonu University, Malatya, Turkey, Department of Medical Oncology, Gazi University, Ankara, Turkey, Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, Department of Medical Oncology, Karadeniz Teknik University, Trabzon, Turkey, Department of Medical Oncology, Dicle University, Diyarbakir, Turkey, Department of Medical Oncology, Istanbul University, Istanbul, Turkey, Department of Medical Oncology, Atatürk University, Erzurum, Turkey, Department of Medical Oncology, Okmeydani Education and Research Hospital, Istanbul University, Istanbul, Turkey, Department of Medical Oncology, Konya Numune Hospital, Konya, Turkey, Department of Medical Oncology, Mersin University, Mersin, Turkey, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Turkey, Department of Medical Oncology, Sakarya University, Sakarya, Turkey, Department of Medical Oncology, Gaziosmanpasa University, Yozgat, Turkey, Department of Medical Oncology, Ankara Onkoloji Education and Research Hospital, Turkey, Department of Medical Oncology, Afyon Kocatepe University, Afyon, Turkey, Department of Medical Oncology, Mugla Sitki Kocman University, Mugla, Turkey, Department of Medical Oncology, Bezmialem Vakif University, Istanbul, Turkey, Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey, and Department of Medical Oncology, Kent Hospital, Istanbul, Turkey

Subjects
Adult, Male, 0301 basic medicine, Oncology, Prognostic variable, medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, Medical Oncology, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, Cranial Irradiation, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Lung cancer, non-small cell lung cancer, Aged, Proportional Hazards Models, Aged, 80 and over, Chemotherapy, Univariate analysis, Brain Neoplasms, business.industry, Proportional hazards model, A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)-, JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, ss.578-582, 2018 [Inal A., Kodaz H., Odabas H., Duran A. O. , Seker M. M. , Inanc M., ELKIRAN E. T. , Gunaydin Y., Menekse S., Topcu T. O. , et al., -Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases], prognostic factors, Brain metastases, General Medicine, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, medicine.disease, respiratory tract diseases, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Female, Non small cell, business
Abstract

WOS: 000435353000019, PubMed ID: 29893321, Purpose: Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the median survival is only 1 month. However, it is difficult to treat brain metastases with systemic chemotherapy since the agents have difficulty crossing the blood-brain barrier. Therefore, it is important to estimate the patient's survival prognosis. The aim of this study was to analyze prognostic factors for survival in Turkish patients who received chemotherapy after cranial irradiation for NSCLC with brain metastases. Methods: We retrospectively reviewed 698 patients with brain metastases resulting from NSCLC. Ten potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with overall survival (OS). Results: Among the 10 variables for univariate analysis, six were identified to have prognostic significance; these included sex, smoking history, histology, number of brain metastases, extracranial metastases, and neurosurgical resection. Multivariate analysis by the Cox proportional hazard model showed that a smoking history, extracranial metastases, and neurosurgical resection were independent negative prognostic factors for OS. Conclusion: Smoking history, extracranial metastases, and neurosurgical resection were considered independent negative prognostic factors for OS. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for more appropriate treatment options.

Published
2018
Full Text
View/download PDF

17. Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury

Author

Ali Yilmaz, A Kerim Turesin, Köksal Deveci, Nalan Akgul Babacan, Turgut Kacan, Ayse Seker, Mehmet Metin Seker, Enver Sancakdar, and Seker, M.M., Medical Oncology Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Deveci, K., Biochemistry Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Seker, A., Public Health Directorate, Sivas, Turkey -- Sancakdar, E., Biochemistry Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Yilmaz, A., Internal Medicine Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Kerim Turesin, A., Internal Medicine Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Kacan, T., Medical Oncology Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey -- Babacan, N.A., Medical Oncology Department, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey

Subjects
Male, Cancer Research, Organoplatinum Compounds, Epidemiology, Urine, Docetaxel, Gastroenterology, Deoxycytidine, Carboplatin, chemistry.chemical_compound, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Nephrotoxicity, Cancer, Platin chemotherapy, Neutrophil gelatinase-associated lipocalin, Acute kidney injury, Acute Kidney Injury, Middle Aged, Prognosis, Lipocalins, Oxaliplatin, Oncology, Creatinine, Female, Taxoids, Fluorouracil, medicine.drug, Adult, medicine.medical_specialty, Paclitaxel, Urinary system, Lipocalin-2, Internal medicine, Proto-Oncogene Proteins, medicine, Biomarkers, Tumor, Humans, Capecitabine, Aged, Neoplasm Staging, Cisplatin, business.industry, Public Health, Environmental and Occupational Health, medicine.disease, Gemcitabine, chemistry, Immunology, business, Acute-Phase Proteins, Follow-Up Studies
Abstract

Asian Pacific Organization for Cancer Prevention, Background: Acute kidney injury is an important issue in chemotherapy receiving patients an neutrophil gelatinase-associated lipocalin has been proposed as a novel marker. We here aimed to assess the role of urinary levels for assessment after platin exposure. Materials and Methods: Patients who had treated with cisplatin or carboplatin or oxaliplatin containg regimens were included in this study. Baseline and postchemotherapy serum urea, creatinine, urine neutrophil gelatinase-associated lipocalin and urine creatinine levels were determined. To avoid the effects of hydration during chemotherapy infusion the urinary neutrophil gelatinase-associated lipocalin/urine creatinine ratio was used to determine acute kidney injury. Results: Of a total of 42 patients receiving platin compounds,14 (33.3%) received cisplatin containing regimens, 14 (33.3%) received carboplatin and 14 (33.3%) oxaliplatin. The median age was 60 (37-76) years. Nineteen of the patients (45.2%) had lung cancer, 12 (28.6%) colorectal cancer and 11 (26.2%) others. The median pre and post chemotherapy urine neutrophil gelatinase-associated lipocalin/urine creatinin ratio was 15.6 ng/mg and 35.8 ng/mg (p=0.041) in the cisplatin group, 32.5 ng/mg and 86.3 ng/mg (p=0.004) in the carboplatin group and 40.9 ng/mg and 62.3 ng/ mg (p=0.243) in the oxaliplatin group. Conclusions: Nephrotoxicity is a serious side effect of chemotherapeutic agentslike cisplatin and carbopaltin, but only to a lower extent oxaliplatin. All platin compounds must be used carefully and urine neutrophil gelatinase-associated lipocalin measurement seems to be promising in detecting acute kidney injury earlier than with creatinine., Seker, M.M.; Medical Oncology Department, Faculty of Medicine, Cumhuriyet UniversityTurkey

Published
2015

18. What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study

Author

Zuhat Urakci, Zeynep Oruç, Muhammet Ali Kaplan, Kezban Nur Pilanci, Turkan Ozturk Topcu, Nuriye Ozdemir, Faysal Dane, Mukremin Uysal, Ulku Yalcintas Arslan, Mahmut Gumus, Dogan Koca, Asude Aksoy, Alper Sevinc, Abdurrahman Isikdogan, Ramazan Yildiz, Mehmet Metin Seker, Mehmet Kucukoner, Mustafa Karaagac, Caglayan Geredeli, and Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey -- Dicle Univ, Fac Med, Diyarbakir, Turkey -- Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey -- Ankara Oncol Training & Res Hosp, Ankara, Turkey -- Konya Numune Training & Res Hosp, Dept Med Oncol, Konya, Turkey -- Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- Specialty Oncol, Van, Turkey -- Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey -- Marmara Univ, Med Oncol, Istanbul, Turkey -- Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey -- Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- Inonu Univ, Fac Med, Dept Med Oncol, Malatya, Turkey -- Dicle Univ, Oncol Hosp, Diyarbakir, Turkey -- Bilim Univ, Dept Med Oncol, Istanbul, Turkey -- Karadeniz Tech Univ, Sch Med, Trabzon, Turkey -- Konya Necmeddin Erbakan Univ, Meram Sch Med, Diyarbakir, Turkey -- Gazi Univ, Fac Med, Dept Med Oncol, Ankara, Turkey -- Dicle Univ, Sch Med, Diyarbakir, Turkey

Subjects
Cancer Research, Pediatrics, medicine.medical_specialty, business.industry, Colorectal cancer, education, food and beverages, +25+years%29+colorectal+cancer+%28CRC%29%3F+An+Anatolian+Society+of+Medical+Oncology+Study%2E-%2C+Annual+Meeting+of+the+American-Society-of-Clinical-Oncology+%28ASCO%29+%2F+Clinical+Science+Symposium+on+Predicting+and+Improving+Adverse+Outcomes+in+Older+Adults+with+Cancer%2C+Illinois%2C+Amerika+Birleşik+Devletleri%2C+29+Mayıs+-+02+Haziran+2015%2C+cilt%2E33%22">Kaplan M. A. , Urakci Z., Gumus M., Arslan U. Y. , Geredeli C., Ozdemir N., Koca D., Oruc Z., Uysal M., Dane F., et al., -What are the differences between young (25 years) and adults (> 25 years) colorectal cancer (CRC)? An Anatolian Society of Medical Oncology Study.-, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, medicine.disease, digestive system diseases, Oncology, Medicine, Young adult, business, neoplasms
Abstract

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL, WOS: 000358036902751, …, Amer Soc Clin Oncol

Published
2015

19. Isolated Testicular Metastasis of Gastric Cancer

Author

Dogan Uncu, Sezer Kulaçoglu, Sener Cihan, Nuriye Ozdemir, Sercan Aksoy, Zafer Arik, Burak Civelek, Nurullah Zengin, Mehmet Ali Nahit Sendur, Tugba Kos, Sebnem Yaman, and Mehmet Metin Seker

Subjects
Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Cancer metastasis, Testicular metastasis, Testicular Neoplasms, Stomach Neoplasms, Internal medicine, medicine, Humans, Stomach cancer, Lung, business.industry, digestive, oral, and skin physiology, Gastroenterology, Cancer, Middle Aged, Prognosis, medicine.disease, Adenocarcinoma, Mucinous, digestive system diseases, Radiation therapy, Leukemia, medicine.anatomical_structure, Prostate gland, Tomography, X-Ray Computed, business
Abstract

Secondary neoplasms of the testis are uncommon and less than 2% of all testicular cancers. Other than leukemia and lymphomas, the most common sites from which metastases occur are the lung and prostate gland. However, here, we report gastric cancer metastasis to the testis, an extremely rare site for gastric adenocarcinomas. We also review the cases of testicular metastasis arising from stomach cancer.

Published
2011
Full Text
View/download PDF

20. Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells

Author

Bülent Saraç, Turgut Kacan, Aykut Bahceci, Nalan Akgul Babacan, Mehmet Metin Seker, Selen Baloglu Kacan, Ahmet Altun, Gulsah Altun, [Kacan, Turgut -- Seker, Mehmet Metin -- Bahceci, Aykut -- Babacan, Nalan] Cumhuriyet Univ, Dept Med Oncol, Sivas, Turkey -- [Altun, Gulsah Gultekin -- Kacan, Selen Baloglu] Sivas Numune Hosp, Dept Internal Med, Sivas, Turkey -- [Altun, Ahmet -- Sarac, Bulent] Sivas Numune Hosp, Dept Pharmacol, Sivas, Turkey, and Altun, Ahmet -- 0000-0003-2056-8683

Subjects
Sorafenib, Niacinamide, Vascular Endothelial Growth Factor A, Cancer Research, Epidemiology, Cell Survival, medicine.medical_treatment, Drug Evaluation, Preclinical, Estrogen receptor, Tyrosine kinase inhibitor, Antineoplastic Agents, Breast Neoplasms, Pharmacology, Lapatinib, Targeted therapy, Breast cancer, breast cancer, Growth factor receptor, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Molecular Targeted Therapy, lapatinib, skin and connective tissue diseases, Protein Kinase Inhibitors, business.industry, Phenylurea Compounds, Public Health, Environmental and Occupational Health, Cancer, Drug Synergism, medicine.disease, ErbB Receptors, Oncology, MCF-7, MCF-7 Cells, Quinazolines, sorafenib, Female, business, medicine.drug
Abstract

WOS: 000336834500041, PubMed ID: 24815468, Background: Breast cancer evolution and tumor progression are controlled by complex interactions between steroid receptors and growth factor receptor signaling. Aberrant growth factor receptor signaling can augment or suppress estrogen receptor function in hormone-dependent breast cancer cells. Thus, we aimed to investigate antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells. Materials and Methods: Cytotoxicity of the sorafenib and lapatinib was tested in MCF-7 cells by XTT assays. 50, 25, 12.5 and 6.25 mu M concentrations of sorafenib and 200, 100, 50 and 25 mu M concentrations of lapatinib were administered alone and in combination. Results were evaluated as absorbance at 450nM and IC50 values are calculated according to the absorbance data Results: Both sorafenib and lapatinib showed concentration dependent cytotoxic effects on MCF-7 cells. Sorafenib exerted cytotoxic effects with an IC50 value of 32.0 mu M; in contrast with lapatinib the IC50 was 136.6 mu M. When sorafenib and lapatinib combined, lapatinib increased cytotoxic effects of sorafenib at its ineffective concentrations. Also at the concentrations where both drugs had cytotoxic effects, combination show strong anticancer effects and killed approximately 70 percent of breast cancer cells. Conclusions: Combinations of tyrosine kinase inhibitors and cytotoxic agents or molecular targeted therapy has been successful for many types of cancer. The present study shows that both sorafenib and lapatinib alone are effective in the treatment of breast cancer. Also a combination of these two agents may be a promising therapeutic option in treatment of breast cancer.

Published
2014

21. Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology

Author

Aydin Ciltas, Burcu Yapar Taskoylu, Utku Oflazoglu, Mustafa Benekli, Murat Akyol, Mehmet Metin Seker, Ayse Ocak Duran, Alper Sevinc, Muhammed Bulent Akinci, Aziz Karaoglu, Sener Cihan, Caglayan Geredeli, Hilmi Kodaz, Umut Kefeli, Ömer Yazici, Didem Tastekin, Banu Ozturk, Umut Demirci, Mukremin Uysal, Suleyman Buyukberber, Ankara Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkey -- Dokuz Eylul Univ, Dept Med Oncol, Izmir, Turkey -- Trakya Univ, Edirne, Turkey -- Gazi Univ, Dept Med Oncol, Ankara, Turkey -- Goztepe Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Izmir Katip Celebi Univ, Dept Med Oncol, Izmir, Turkey -- Gaziosmanpasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkey -- Konya Numune Training & Res Hosp, Dept Med Oncol, Konya, Turkey -- Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Istanbul Univ, Inst Oncol, Istanbul, Turkey -- Gaziantep Univ, Dept Med Oncol, Gaziantep, Turkey -- Ankara Ataturk Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey -- Afyon Kocatepe Univ, Dept Med Oncol, Afyon, Turkey -- Pamukkale Univ, Dept Med Oncol, Denizli, Turkey -- Erciyes Univ, Fac Med, Dept Med Oncol, Kayseri, Turkey -- Dr AY Ankara Oncol Training & Res Hosp, Ankara, Turkey, and KEFELI, UMUT -- 0000-0001-6126-5377

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Abiraterone acetate, Castration resistant, medicine.disease, humanities, body regions, chemistry.chemical_compound, Prostate cancer, Docetaxel, chemistry, Internal medicine, Medicine, In patient, business, medicine.drug
Abstract

50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL, WOS: 000358613200846, …, Amer Soc Clin Oncol

Published
2014

22. Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experience

Author

Dogan Uncu, Ayse Seker, Nurullah Zengin, Nuriye Ozdemir, Mehmet Metin Seker, Tugba Kos, Sercan Aksoy, [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Kos, Tugba] Manisa State Hosp, Manisa, Turkey -- [Ozdemir, Nuriye -- Uncu, Dogan -- Zengin, Nurullah] Mutki State Hosp, Bitlis, Turkey -- [Seker, Ayse] Numune Educ & Res Hosp, Ankara, Turkey -- [Aksoy, Sercan] Hacettepe Univ, Inst Canc, Ankara, Turkey, Aksoy, Sercan -- 0000-0003-4984-1049, and İç Hastalıkları

Subjects
Thorax, Adult, Male, Cancer Research, medicine.medical_specialty, Turkey, Epidemiology, Soft Tissue Neoplasms, Disease, Sarcoma, Ewing, Disease-Free Survival, Young Adult, Abdomen, Antineoplastic Combined Chemotherapy Protocols, medicine, Adult cases, Humans, Retrospective Studies, Spinal Neoplasms, business.industry, Public Health, Environmental and Occupational Health, Soft tissue, Extremities, medicine.disease, Primary tumor, Combined Modality Therapy, Vertebra, Surgery, Survival Rate, medicine.anatomical_structure, Oncology, Head and Neck Neoplasms, Localized disease, Female, Sarcoma, prognosis, business, Ewing sarcoma
Abstract

WOS: 000332001000055, PubMed ID: 24528050, Background: Ewing sarcoma is a small round cell tumor arising from soft tissue and bone that predominantly affects children and adolescents. The most unfavorable prognostic factor is the presence of distant metastasis at the time of diagnosis. Materials and Methods: The records of 26 Ewing sarcoma patients (14 male, 12 female) were re-evaluated retrospectively. Results: The median age was 26.5 (19-42) years. Eight patients (31%) showed a primary tumor in their extremities, 8 (31%) in the thorax, 4 (15%) at the vertebra, 4 (15%) in the head and neck, and 2 (8%) in the abdomen. Five patients (19%) had distant metastasis at diagnosis. The median progression-free survival was 72 months and 10 months in localized and metastatic disease, respectively (p=0.005). The overall survival rate was 19 months in metastatic disease, and the 5-year overall survival rate was 64% in localized disease (p=0.006). Patients who had localized disease in the extremities and were under age 30 had a favorable prognosis. Conclusions: Although Ewing sarcoma is a tumor affecting children and adolescents, it may be seen in adults, where the prognosis is generally worse. Although it is a highly malignant tumor, it is possible to achieve improved survival with combined modality treatments.

Published
2014

23. Prognostic value of serum TIE-2 and vascular endothelial growth factor levels in gastric cancer patients

Author

Nalan Akgul Babacan, Turgut Kaçan, Ayse Seker, Aykut Bahceci, Mehmet Metin Seker, Enver Sancakdar, and Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Biochem, Sivas, Turkey -- Ibni Sina Publ Hlth Care Ctr, Sivas, Turkey

Subjects
Cancer Research, biology, business.industry, Angiogenesis, VEGF receptors, Cancer, medicine.disease, Metastasis, Vascular endothelial growth factor, chemistry.chemical_compound, Oncology, chemistry, medicine, Cancer research, biology.protein, Tumor growth, business, Tyrosine kinase
Abstract

50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL, WOS: 000358613200491, …, Amer Soc Clin Oncol

Published
2014

24. Serum leptin and adiponectin levels and relationship with prognosis in lung cancer

Author

Mehmet Metin Seker, Nalan Akgul Babacan, Gulsah Altun, Aydin Nadir, Aykut Bahceci, Melih Kaptanoglu, Turgut Kaçan, Enver Sancakdar, and Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Biochem, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Thorac Surg, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Internal Med, Sivas, Turkey

Subjects
Cancer Research, medicine.medical_specialty, Adiponectin, Mechanism (biology), business.industry, Cancer, medicine.disease, Endocrinology, Oncology, Internal medicine, Serum leptin, medicine, Lung cancer, business, Hormone
Abstract

50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL, WOS: 000358613201323, …, Amer Soc Clin Oncol

Published
2014

25. Clinicopathologic Features And Prognosis Of Osteosarcoma In Turkish Adults

Author

Nuriye Ozdemir, Sercan Aksoy, Ayse Seker, Mehmet Metin Seker, Nurullah Zengin, Dogan Uncu, Beslenme ve Diyetetik, [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Seker, Ayse] Publ Hlth Directorate, Sivas, Turkey -- [Aksoy, Sercan] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey -- [Ozdemir, Nuriye -- Uncu, Dogan -- Zengin, Nurullah] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey, and Aksoy, Sercan -- 0000-0003-4984-1049

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Adolescent, Turkey, Epidemiology, medicine.medical_treatment, Bone Neoplasms, Disease-Free Survival, Cohort Studies, Young Adult, Internal medicine, medicine, adults, Humans, Progression-free survival, Young adult, Pathological, Aged, Neoplasm Staging, Retrospective Studies, Chemotherapy, Osteosarcoma, L-Lactate Dehydrogenase, treatment, business.industry, Public Health, Environmental and Occupational Health, Retrospective cohort study, Middle Aged, Alkaline Phosphatase, Prognosis, medicine.disease, Chemotherapy regimen, Surgery, Fractures, Spontaneous, Female, prognosis, business, Cohort study
Abstract

WOS: 000338633500034, PubMed ID: 24870753, Background: Osteosarcomas are the most common solid malignancies of bone. In the last two decades there have been no concrete developments in their systemic treatment. In this trial we aimed to present our osteosarcoma patient clinical and demographic outcomes. Materials and Methods: Patients treated and followed up for osteosarcoma in Ankara Numune Education and Research Hospital from 2002 to 2012 were reviewed retrospectively. Results: A total of 21 patients (15 male, 6 female) were diagnosed with osteosarcoma. The disease was located at extremities in 76% and in 14% was metastatic at the time of diagnosis. Median disease free survival (DFS) was 36 months in non-metastatic patients and median progression free survival (PFS) was 2 months in metastatic patients (p

Published
2014

26. Treatment and prognosis of breast cancer in elderly: Different from young patients?

Author

Birsen Yücel, Turgut Kaçan, Nalan Akgün Babacan, Aykut Bahceci, A. Ay Eren, Mehmet Metin Seker, A. Seker, G. Celasun, Seher Bahar, M. Fuat Eren, [Seker, M. Metin -- Kacan, T. -- Babacan, N. -- Bahceci, A.] Cumhuriyet Univ, Fac Med, Dept Med Oncol, TR-58140 Sivas, Turkey -- [Yucel, B. -- Eren, A. Ay -- Bahar, S. -- Celasun, G. -- Eren, M. Fuat] Cumhuriyet Univ, Fac Med, Dept Radiat Oncol, TR-58140 Sivas, Turkey -- [Seker, A.] Mutki State Hosp, Minist Hlth, Bitlis, Turkey, and Eren, Mehmet F -- 0000-0002-6531-978X

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Side effect, business.industry, medicine.medical_treatment, Incidence (epidemiology), University faculty, Subgroup analysis, medicine.disease, Prognosis, humanities, Radiation therapy, Clinical trial, Treatment, Breast cancer, Elderly, Internal medicine, medicine, Geriatrics and Gerontology, business, Gerontology
Abstract

WOS: 000339706300007, Purpose: The incidence of breast cancer increases with advanced age; 80% of patients are older then 50 years and 40% of patients are older then 65 years. But clinical trials including elderly patient are unsatisfactory. Most of the treatment decisions are based on retrospective subgroup analysis and extrapolations from studies including young patients. In this trial we aimed to reevaluate our elderly breast cancer patients' data. Methods: This study includes breast cancer patients age older then 65 years and treated at Cumhuriyet University Faculty of Medicine Medical Oncology Department. The patients' data were reviewed retrospectively. Results: Seventy-nine patient's data, who had treated and followed up at our institution were evaluated. Seventy-one (89.9%) patients were non-metastatic at the time of diagnosis. Chemotherapy and/or radiotherapy related side effects had detected in 66.6% of patients. The only grade 4 side effect was skin reaction in 1 patient. During the follow up period progression had developed at 100% of metastatic patients. In non-metastatic group, 2 patients (2.7%) had local relapse and 12 patients (16.6%) had distant metastasis. Conclusion: Elderly patients have more favorable prognostic factors from younger patients but their survival is not as good as expected. Chemotherapy or radiotherapy is not more toxic in elderly patients. So with close follow up elderly breast cancer patients should be treated as younger patients. (C) 2014 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.

Published
2014

27. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for lung cancers?

Author

Birsen Yücel, Nalan Akgul Babacan, Mehmet Metin Seker, Aykut Bahceci, Mustafa Asim Gedikli, Turgut Kaçan, Saadettin Kilickap, and Cumhuriyet Univ, Fac Med, Med Oncol Dept, Sivas, Turkey -- Cumhuriyet Univ Hosp, Radiat Oncol, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Internal Med, Sivas, Turkey -- Hacettepe Univ, Inst Canc, Ankara, Turkey

Subjects
Cancer Research, Prognostic factor, Lung, medicine.anatomical_structure, Oncology, business.industry, Immunology, Medicine, Disease, Neutrophil to lymphocyte ratio, business
Abstract

50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL, WOS: 000358613201351, …, Amer Soc Clin Oncol

Published
2014

28. Do neutrophil gelatinase-associated lipocalin and interleukin-18 predict renal dysfunction in patients with familial Mediterranean fever and amyloidosis?

Author

Serdal Korkmaz, Abdulkadir Deniz, Enver Sancakdar, Ali Ugur Uslu, Köksal Deveci, Mehmet Metin Seker, Soner Senel, Mehmet Şencan, Filiz Alkan, Hülya Deveci, and [Deveci, Koksal -- Sancakdar, Enver -- Alkan, Filiz] Cumhuriyet Univ, Sch Med, Dept Clin Biochem, TR-58140 Sivas, Turkey -- [Korkmaz, Serdal -- Sencan, Mehmet] Cumhuriyet Univ, Sch Med, Dept Hematol, TR-58140 Sivas, Turkey -- [Senel, Soner] Erciyes Univ, Sch Med, Dept Rheumatol, Kayseri, Turkey -- [Deveci, Hulya] Numune State Hosp, Dept Phys Med & Rehabil, Sivas, Turkey -- [Uslu, Ali U.] Cumhuriyet Univ, Sch Med, Dept Internal Med, TR-58140 Sivas, Turkey -- [Deniz, Abdulkadir] Family Hlth Govt Clin, Dept Family Hlth, Sivas, Turkey -- [Seker, Mehmet M.] Cumhuriyet Univ, Sch Med, Dept Med Oncol, TR-58140 Sivas, Turkey

Subjects
Adult, Male, medicine.medical_specialty, estimated glomerular filtration rate, Familial Mediterranean fever, Renal function, Lipocalin, Critical Care and Intensive Care Medicine, Kidney, Gastroenterology, interleukin-18, Excretion, familial Mediterranean fever, Lipocalin-2, Internal medicine, Proto-Oncogene Proteins, Medicine, Humans, In patient, Prospective Studies, Prospective cohort study, business.industry, Amyloidosis, Interleukin-18, neutrophil gelatinase-associated lipocalin, General Medicine, Middle Aged, medicine.disease, Lipocalins, Familial Mediterranean Fever, Nephrology, Immunology, Interleukin 18, Female, business, Biomarkers, Acute-Phase Proteins, Glomerular Filtration Rate
Abstract

WOS: 000333169100003, PubMed ID: 24320110, Background: The aim of this study was to evaluate whether neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 (IL-18) predict renal disfunction in patients with familial Mediterranean fever (FMF). Methods: This prospective study consisted of 102 patients with FMF in attack-free period, and 40 matched healthy controls. Of the patients, nine were diagnosed as amyloidosis. The patients were divided into two groups according to eGFR as below 120 mL per minute and above 120 mL per minute. Also, patients were divided into three groups according to the degree of urinary albumin excretion as normoalbuminuric, microalbuminuric, and macroalbuminuric. The serum levels of IL-18 (sIL-18) and NGAL (sNGAL), and urinary levels of IL-18 (uIL-18) and NGAL (uNGAL) were measured by using ELISA kits. Results: The levels of sIL-18, sNGAL, uIL-18, and uNGAL were detected significantly higher in FMF patients, particularly in patients with amyloidosis, when compared to controls. sNGAL, uIL-18, and uNGAL were significantly higher in patients with eGFR < 120 mL per minute than in patients with eGFR >= 120 mL per minute. sNGAL, uIL-18, and uNGAL were correlated significantly with urinary albumin excretion, additionally, were inverse correlated with eGFR. The most remarkable findings of this study are of the higher values of sIL-18, sNGAL, uIL-18, and uNGAL in both normoalbuminuric FMF patients and patients with eGFR >= 120 mL per minute. Conclusions: The results of this study suggest that sIL-18, uIL-18, sNGAL, and uNGAL are reliable markers of early renal disfunction in FMF patients, and may let us take measures from the early stage of renal involvement., Research Foundation Council of Cumhuriyet University [T-478], The Research Foundation Council of Cumhuriyet University partly supported this study (Project No: T-478). The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Published
2013

29. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients

Author

Kaan Helvaci, Ayşe Demirci, Necati Alkis, Saadet Tokluoglu, Şengül Cangür, Ali Inal, Oznur Bal, Abdurrahman Isikdogan, Mevlude Inanc, Berna Oksuzoglu, Fisun Ardic Yukruk, Ayse Durnali, Mehmet Metin Seker, Tulay Akman, and [Durnali, Ayse -- Alkis, Necati -- Bal, Oznur -- Demirci, Ayse -- Helvaci, Kaan -- Oksuzoglu, Berna] Dr AY Ankara Oncol Training & Res Hosp, Dept Med Oncol, TR-06200 Ankara, Turkey -- [Cangur, Sengul] Duzce Univ, Fac Med, Dept Biostat & Med Informat, Duzce, Turkey -- [Yukruk, Fisun Ardic] Dr AY Ankara Oncol Training & Res Hosp, Dept Pathol, TR-06200 Ankara, Turkey -- [Inal, Ali -- Isikdogan, Abdurrahman] Dicle Univ, Fac Med, Dept Med Oncol, Diyarbakir, Turkey -- [Tokluoglu, Saadet] Guven Hosp, Dept Med Oncol, Ankara, Turkey -- [Seker, Mehmet Metin] Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- [Akman, Tulay] Dokuz Eylul Univ, Fac Med, Dept Med Oncol, Izmir, Turkey -- [Inanc, Mevlude] Erciyes Univ, Fac Med, Dept Med Oncol, Kayseri, Turkey

Subjects
Male, Adult, Cancer Research, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Bone Neoplasms, Prognostic factors, Gastroenterology, Metastasis, Young Adult, Internal medicine, medicine, Humans, Stage (cooking), Aged, Retrospective Studies, Cancer staging, Chemotherapy, Osteosarcoma, business.industry, Teenage, Hematology, General Medicine, Middle Aged, Prognosis, medicine.disease, Primary tumor, Surgery, Regimen, Treatment Outcome, Oncology, Female, Methotrexate, business, medicine.drug
Abstract

WOS: 000323662900059, PubMed ID: 23749307, The aim of this retrospective, multicenter study was to evaluate clinicopathological characteristics, prognostic factors and treatment outcomes of teenage and adult patients with high-grade osteosarcoma. A total of 240 osteosarcoma patients who were diagnosed and treated from March 1995 to September 2011 were analyzed. Median age was 20 years (range 13-74 years), and 153 patients (63.8 %) were male. Primary tumor localization was extremity in 204 patients (85.4 %), trunk in 21 patients (8.8 %) and head and neck region in 14 patients (5.9 %). According to American Joint Committee on Cancer staging system, 186 patients (77.5 %) were stage II, 3 (1.3 %) were stage III and 48 (20.0 %) were stage IV. Median overall survival (OS) was 55 months (95 % CI 36.8-73.1 months). OS after 2, 5 and 10 years were 67, 49 and 42 %, respectively. Univariable analysis for OS showed that male gender (p = 0.032), high baseline lactate dehydrogenase (LDH) level (p < 0.001), high baseline serum alkaline phosphatase level (p = 0.002), telangiectatic subtype (p = 0.023), presence of metastasis at diagnosis (p < 0.001), presence of tumor positive margins after primary surgery (p = 0.015), poor pathological response to preoperative chemotherapy (p = 0.006) and presence of recurrent disease during follow-up period (p < 0.001) were significantly associated with poor survival. Patientswho received postoperative methotrexate plus doxorubicin plus cisplatin (M + A + P) combination regimen (p = 0.019), underwent surgery for recurrent disease (p < 0.001) and received chemotherapy for recurrent disease (p < 0.001) had longer OS. Inmultivariable analysis for OS, only high LDH level (p = 0.002) and the presence of metastasis at diagnosis (p = 0.011) were associated with poor OS, whereas the patients who received chemotherapy for recurrent disease had a longer OS (p = 0.009).

Published
2013

30. Successful treatment of chronic hiccup with baclofen in cancer patients

Author

Sercan Aksoy, Burak Civelek, M. Bülent Akıncı, Dogan Uncu, Nurullah Zengin, Nuriye Ozdemir, and Mehmet Metin Seker

Subjects
Male, Cancer Research, Baclofen, Metoclopramide, medicine.medical_treatment, Antineoplastic Agents, Hiccup, chemistry.chemical_compound, Nifedipine, Stomach Neoplasms, Haloperidol, medicine, Humans, Chlorpromazine, Chemotherapy, business.industry, Muscle Relaxants, Central, organic chemicals, musculoskeletal, neural, and ocular physiology, Lymphoma, Non-Hodgkin, Cancer, Hematology, General Medicine, Middle Aged, medicine.disease, body regions, Treatment Outcome, nervous system, Oncology, chemistry, Anesthesia, Chronic hiccup, business, medicine.drug
Abstract

Chronic hiccup is an infrequent but distressing symptom in patients with advanced cancer. A series of drugs (chlorpromazine, haloperidol, nifedipine, metoclopramide, baclofen) have been used to treat hiccup without definitive results. Some authors have suggested a possible role of baclofen in the treatment of chronic hiccup. We report three cases of chronic hiccup in patients with cancer successfully treated with baclofen.

Published
2011

31. Türk hipertansiyon hastalarında mikroalbuminüri sıklığı ve ilişkili kardiyovasküler risk faktörleri

Author

V Çam, M Etemoglu, Sebahattin Ateşal, E Koçak, Bulent Polat, Meral Kayıkçıoğlu, Yekta Gürlertop, Cem Köz, Ö Özbek, H Yegin, Ceyhun Ceyhan, K Dönmez, B Tosun, H Atmaca, G Dönmez, B. ilerigelen, H Bozdemir, I Biyik, A Sökmen, F Koca, Kenan Övünç, Ramazan Topsakal, Sadi Gulec, O Tartanoglu, Kurtulus Ozdemir, A Fiskeci, E Akarca, Ahmet Sakalli, A Yavuz, M Bilaloglu, Giray Kabakci, T Keleş, F K Inceer, H Tunar, Ş Coşkun, M Şan, S C Turan, Serkan Topaloglu, Irem Dincer, S Yorganci, R Yoldaş, Ömer Kozan, I T Kurt, Mehmet İlker Gökçe, Hakan Kültürsay, A Yilmaz, C Genç, M Ö Sunay, K Tigen, A Sinci, T Ulusoy, Şükrü Ünal, Filiz Özerkan, Sinan Aydoğdu, H Bozkurt, N S Aran, Ercan Varol, O Sancaktar, A Delice, H Tikiz, Emin Evren Özcan, Fatih Sinan Ertaş, H Kaymak, E Semiz, C Rezzagil, I Susal, N Çam, F Özmen, Vedat Aytekin, S Çolak, A Keskin, E Acartürk, N Ata, Oben Döven, H Boga, H Vural, E Şensoy, A Lazoglu, I Özdogru, Y Balbay, Dursun Aras, J Jordan, Dilek Yeşilbursa, H Akgöz, E Onrat, Y Selçoki, Dilek Ural, R Uçar, Sinan Kahraman, H Gök, M T Sirkeci, T Peker, M Bilge, Mehmet Metin Seker, C Agçal, D Aytekin, S Toktaş, A Birdane, Y Yakar, A H Sözcüer, U Sümerkan, S Sakalli, Mehmet Oc, N Sönmez, M Bostan, A Akyüz, Adnan Abaci, V Koca, K Şahna, K Aytemir, Yuksel Cavusoglu, M Tahtasiz, Adalet Gürlek, O Ergene, V Gökçe, I Dogru, M Dagalp, Cuneyt Turkoglu, Ramazan Akdemir, C Uyan, Ahmet Vural, R Kargin, Enver Atalar, A Ünsal, A Bitigen, T T Gündogdu, Kaan Kulan, B Erol, A U Gülmez, Merih Kutlu, K Öztaş, I Tandogan, A Karanfil, Mustafa Polat, S Cinsoy, A Sert, M Çakmak, Ali Ergin, T Durmaz, A Aydinlar, P Pinar, A Kerpeten, Serdar Sevimli, Saide Aytekin, C Nazli, T Kirat, Zeynep Tartan, H Atasever, A Çamsari, A Aribaş, N Keser, Aydan Ongun Ozdemir, N Coşkun, Mehmet Yazici, Y Erzurum, Nevrez Koylan, Mustafa Yilmaz, M Ş Güçel, A E Kiliçoglu, O H Elönü, A Köşüş, G Topkara, G Daş, L Saraç, M Melek, D Gaffari, A Bayram, Z Tosun, K Kaya, Mahmut Şahin, Z Işilak, A Içli, Necla Ozer, Mustafa Kılıçkap, E Aygün, H Gündüz, H Öney, A Daver, Z Kaplan, M Gürsürer, Huseyin Arinc, A Irmak, Osman Alper Onbasili, F V Ulusoy, Mehmet Ridvan Yalcin, M Şerifi, Ahmet Temizhan, Ahmet Çelik, C Kirdar, S Mecit, Cihan Örem, A Güven, Kozan, Ö., Dokuz Eylül University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Özcan, E.E., Izmir Hospital, Izmir, Turkey -- Sancaktar, O., Istanbul Şafak Hospital, Istanbul, Turkey, Akdeniz University Medical Faculty, Department of Cardiology, Antalya, Turkey -- Kabakci, G., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Sözcüer, A.H., Merkez Efendi State Hospital, Cardiology Clinic, Manisa, Turkey -- Kerpeten, A., Kütahya State Hospital, Cardiology Clinic, Kütahya, Turkey -- Delice, A., Kizilay Health Center, Cardiology Polyclinic, Kayseri, Turkey -- Içli, A., Konya Municipality Hospital, Cardiology Clinic, Konya, Turkey -- Sökmen, A., Sütçü Imam University Medical Faculty, Department of Cardiology, Kahramanmaraş, Turkey -- Gürlek, A., Ankara University Medical Faculty, Department of Cardiology, Ibn-i Sina Hospital, Ankara, Turkey -- Abaci, A., Gazi University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Bayram, A., Erzurum Numune State Hospital, Cardiology Clinic, Erzurum, Turkey -- Köşüş, A., Ordu Medical Center, 19 Eylül Internal Diseases Polyclinic, Ordu, Turkey -- Çamsari, A., Mersin University Medical Faculty, Department of Cardiology, Mersin, Turkey -- Sakalli, A., Afyon State Hospital, Cardiology Clinic, Afyon, Turkey -- Sert, A., Beypazari State Hospital, Cardiology Clinic, Ankara, Turkey -- Temizhan, A., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Yilmaz, A., Cumhuriyet University Medical Faculty, Department of Cardiology, Sivas, Turkey -- Daver, A., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Aydinlar, A., Uludag University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Ergin, A., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Kiliçoglu, A.E., Elazig State Hospital, Cardiology Clinic, Elazig, Turkey -- Birdane, A., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Aribaş, A., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Lazoglu, A., Intermed Medical Center, Cardiology Clinic, Alanya, Antalya, Turkey -- Özdemir, A., 1 Eylül State Hospital, Cardiology Clinic, Uşak, Turkey -- Fiskeci, A., Balikesir State Hospital, Cardiology Clinic, Balikesir, Turkey -- Çelik, A., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Bitigen, A., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Keskin, A., Akhisar State Hospital, Cardiology Clinic, Manisa, Turkey -- Yavuz, A., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Akyüz, A., Sultan 1. Izzettin Keykavuş State Hospital, Cardiology Clinic, Sivas, Turkey -- Karanfil, A., Fatih University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Ünsal, A., Gölcük State Hospital, Cardiology Clinic, Kocaeli, Turkey -- Sinci, A., Bilecik State Hospital, Cardiology Clinic, Bilecik, Turkey -- Gülmez, A.U., Pamukkale State Hospital, Cardiology Clinic, Denizli, Turkey -- Irmak, A., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Vural, A., Toros State Hospital, Cardiology Clinic, Mersin, Turkey -- Güven, A., Sütçü Imam University Medical Faculty, Department of Cardiology, Kahramanmaraş, Turkey -- Ilerigelen, B., Istanbul University Cerrahpaşa Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Erol, B., Giresun State Hospital, Cardiology Clinic, Giresun, Turkey -- Polat, B., Polatli Duatepe State Hospital, Cardiology Clinic, Ankara, Turkey -- Tosun, B., Aydin 82. Yil State Hospital, Cardiology Clinic, Aydin, Turkey -- Agçal, C., Isparta State Hospital, Cardiology Clinic, Isparta, Turkey -- Genç, C., Gülhane Military Medical Academy, Department of Cardiology, Ankara, Turkey -- Kirdar, C., Eskişehir State Hospital, Cardiology Clinic, Eskişehir, Turkey -- Rezzagil, C., Şevket Yilmaz State Hospital, Cardiology Clinic, Bursa, Turkey -- Köz, C., Gülhane Military Medical Academy, Department of Cardiology, Ankara, Turkey -- Nazli, C., Atatürk Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Ceyhan, C., Adnan Menderes University Medical Faculty, Department of Cardiology, Aydin, Turkey -- Örem, C., Karadeniz Technical University Medical Faculty, Department of Cardiology, Trabzon, Turkey -- Uyan, C., Abant Izzet Baysal University Medical Faculty, Department of Cardiology, Bolu, Turkey -- Türkoglu, C., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Gaffari, D., Kizilay Health Center, Cardiology Polyclinic, Üsküdar, Istanbul, Turkey -- Aytekin, D., Salihli Public Hospital, Cardiology Clinic, Manisa, Turkey -- Ural, D., Kocaeli University Medical Faculty, Department of Cardiology, Kocaeli, Turkey -- Yeşilbursa, D., Uludag University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Aras, D., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Semiz, E., Pamukkale University Medical Faculty, Department of Cardiology, Denizli, Turkey -- Koçak, E., Evliya Çelebi State Hospital, Cardiology Clinic, Kütahya, Turkey -- Atalar, E., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Varol, E., Süleyman Demirel University Medical Faculty, Department of Cardiology, Isparta, Turkey -- Onrat, E., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Şensoy, E., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Acartürk, E., Çukurova University Medical Faculty, Department of Cardiology, Adana, Turkey -- Akarca, E., Nazilli State Hospital, Cardiology Clinic, Aydin, Turkey -- Aygün, E., Bafra State Hospital, Cardiology Clinic, Samsun, Turkey -- Ertaş, F.S., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Koca, F., Alsancak State Hospital, Cardiology Clinic, Izmir, Turkey -- Özmen, F., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Ulusoy, F.V., Ankara Numune Hospital, 2nd Cardiology Clinic, Ankara, Turkey -- Özerkan, F., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Inceer, F.K., Çorum State Hospital, Cardiology Clinic, Çorum, Turkey -- Dönmez, G., Bakirköy Dr. Sadi Konuk Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Topkara, G., Bandirma State Hospital, Cardiology Clinic, Balikesir, Turkey -- Daş, G., 82. Yil State Hospital, Cardiology Clinic, Adiyaman, Turkey -- Bozkurt, H., Antakya State Hospital, Cardiology Clinic, Antakya, Turkey -- Kültürsay, H., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Tikiz, H., Celal Bayar University Medical Faculty, Department of Cardiology, Manisa, Turkey -- Akgöz, H., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Kaymak, H., Tarsus State Hospital, Cardiology Clinic, Mersin, Turkey -- Öney, H., Artvin State Hospital, Cardiology Clinic, Artvin, Turkey -- Yegin, H., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Boga, H., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Gök, H., Selçuk State Hospital, Cardiology Clinic, Izmir, Turkey -- Vural, H., Vedat Ali Özkan State Hospital, Cardiology Clinic, Kayseri, Turkey -- Atasever, H., Adapazari State Hospital, Cardiology Clinic, Adapazari, Turkey -- Arinç, H., Izzet Baysal University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Bozdemir, H., Buca Seyfi Demirsoy State Hospital, Cardiology Clinic, Izmir, Turkey -- Gündüz, H., Izzet Baysal University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Tunar, H., Salihli State Hospital, Cardiology Clinic, Manisa, Turkey -- Atmaca, H., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Dogru, I., Çukurova State Hospital, Cardiology Clinic, Adana, Turkey -- Özdogru, I., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Susal, I., Karşiyaka State Hospital, Cardiology Clinic, Izmir, Turkey -- Kurt, I.T., Atakalp Heart Hospital, Cardiology Clinic, Izmir, Turkey -- Dinçer, I., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Biyik, I., Uşak State Hospital, Cardiology Clinic, Uşak, Turkey -- Tandogan, I., Cumhuriyet University Medical Faculty, Department of Cardiology, Sivas, Turkey -- Jordan, J., Uludag University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Kulan, K., Trabzon Numune State Hospital, Cardiology Clinic, Trabzon, Turkey -- Şahna, K., Ordu State Hospital, Cardiology Clinic, Ordu, Turkey -- Öztaş, K., Samsun State Hospital, Cardiology Clinic, Samsun, Turkey -- Dönmez, K., Manavgat State Hospital, Cardiology Clinic, Antalya, Turkey -- Övünç, K., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Kaya, K., Bursa State Hospital, Cardiology Clinic, Bursa, Turkey -- Aytemir, K., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Özdemir, K., Selçuk University Medical Faculty, Department of Cardiology, Konya, Turkey -- Tigen, K., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Saraç, L., Istinye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Sirkeci, M.T., Kizilay Health Center, Cardiology Polyclinic, Erzincan, Turkey -- Çakmak, M., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Şahin, M., Ondokuz Mayis University Medical Faculty, Department of Cardiology, Samsun, Turkey -- Kutlu, M., Harput State Hospital, Cardiology Clinic, Elazig, Turkey -- Bilge, M., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Bostan, M., Rize State Hospital, Cardiology Clinic, Rize, Turkey -- Melek, M., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Sunay, M.Ö., Balikesir State Hospital, Cardiology Clinic, Balikesir, Turkey -- Şeker, M., Meram State Hospital, Cardiology Clinic, Konya, Turkey -- Güçel, M.Ş., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Yazici, M., Düzce University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Kayikçioglu, M., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Öç, M., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Gürsürer, M., Karaelmas University Medical Faculty, Department of Cardiology, Zonguldak, Turkey -- Dagalp, M., Ziraat Bank Hospital, Cardiology Clinic, Ankara, Turkey -- Bilaloglu, M., Erzurum Numune State Hospital, Cardiology Clinic, Erzurum, Turkey -- Yalçin, M., GATA Haydarpaşa Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Şerifi, M., Izmit State Hospital, Cardiology Clinic, Kocaeli, Turkey -- Gökçe, M., Karadeniz Technical University Medical Faculty, Department of Cardiology, Trabzon, Turkey -- Kiliçkap, M., Ankara University Medical Faculty, Department of Cardiology, Heart Center, Ankara, Turkey -- Polat, M., Ceyhan State Hospital, Cardiology Clinic, Adana, Turkey -- Şan, M., Çukurova University Medical Faculty, Department of Cardiology, Adana, Turkey -- Tahtasiz, M., Eşrefpaşa Municipality Hospital, Cardiology Clinic, Izmir, Turkey -- Yilmaz, M., Kayseri State Hospital, Cardiology Clinic, Kayseri, Turkey -- Etemoglu, M., Izmir Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Coşkun, N., Harput State Hospital, Cardiology Clinic, Elazig, Turkey -- Aran, N.S., Istanbul University Cerrahpaşa Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Ata, N., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Sönmez, N., Bodrum State Hospital, Cardiology Clinic, Mugla, Turkey -- Çam, N., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Koylan, N., Istanbul University Istanbul Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Özer, N., Iskenderun State Hospital, Cardiology Clinic, Hatay, Turkey -- Keser, N., Maltepe University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Döven, O., Mersin University Medical Faculty, Department of Cardiology, Mersin, Turkey -- Tartanoglu, O., Karaman State Hospital, Cardiology Clinic, Karaman, Turkey -- Ergene, O., Atatürk Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Elönü, O.H., Melikgazi Hospital, Cardiology Clinic, Kayseri, Turkey -- Onbaşili, O.A., Adnan Menderes University Medical Faculty, Department of Cardiology, Aydin, Turkey -- Özbek, Ö., Marmara University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Pinar, P., Manisa State Hospital, Cardiology Clinic, Manisa, Turkey -- Akdemir, R., Düzce University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Kargin, R., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Topsakal, R., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Yoldaş, R., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Uçar, R., Giresun State Hospital, Cardiology Clinic, Giresun, Turkey -- Ateşal, S., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Toktaş, S., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Cinsoy, S., Sabuncuoglu Şerafeddin State Hospital, Cardiology Clinic, Amasya, Turkey -- Güleç, S., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Aytekin, S., Kadir Has University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Çolak, S., Kizilay Health Center, Cardiology Polyclinic, Sivas, Turkey -- Mecit, S., Çanakkale Şehitlik State Hospital, Cardiology Clinic, Çanakkale, Turkey -- Sakalli, S., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Sevimli, S., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Topaloglu, S., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Aydogdu, S., Ankara Numune Hospital, Cardiology Clinic, Ankara, Turkey -- Turan, S.C., Fatih Sultan Mehmet State Hospital, Cardiology Clinic, Istanbul, Turkey -- Kahraman, S., Nigde State Hospital, Cardiology Clinic, Nigde, Turkey -- Yorganci, S., Atatürk State Hospital, Cardiology Clinic, Antalya, Turkey -- Coşkun, Ş., Bursa State Hospital, Cardiology Clinic, Bursa, Turkey -- Ünal, Ş., Nevşehir State Hospital, Cardiology Clinic, Nevşehir, Turkey -- Durmaz, T., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Ulusoy, T., Aksaray State Hospital, Cardiology Clinic, Aksaray, Turkey -- Keleş, T., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Kirat, T., Mugla State Hospital, Cardiology Clinic, Mugla, Turkey -- Gündogdu, T.T., Gebze Fatih Hospital, Cardiology Clinic, Kocaeli, Turkey -- Peker, T., Gemlik State Hospital, Cardiology Clinic, Bursa, Turkey -- Sümerkan, U., Marmara University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Aytekin, V., Kadir Has University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Koca, V., Bursa Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Bursa, Turkey -- Çam, V., Fethiye State Hospital, Cardiology Clinic, Mugla, Turkey -- Gökçe, V., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Gürlertop, Y., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Balbay, Y., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Çavuşoglu, Y., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Erzurum, Y., Eskişehir Yunus Emre State Hospital, Cardiology Clinic, Eskişehir, Turkey -- Selçoki, Y., Fatih University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Yakar, Y., Tokat State Hospital, Cardiology Clinic, Tokat, Turkey -- Işilak, Z., GATA Haydarpaşa Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Tosun, Z., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Kaplan, Z., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Tartan, Z., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey, Zonguldak Bülent Ecevit Üniversitesi, 0-Belirlenecek, Ondokuz Mayıs Üniversitesi, BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Uyan, Cihangir, Aytekin, Saide, Aytekin, Vedat, Kozan, Ö., Dokuz Eylül University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Özcan, E.E., Izmir Hospital, Izmir, Turkey -- Sancaktar, O., Istanbul Şafak Hospital, Istanbul, Turkey, Akdeniz University Medical Faculty, Department of Cardiology, Antalya, Turkey -- Kabakci, G., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Sözcüer, A.H., Merkez Efendi State Hospital, Cardiology Clinic, Manisa, Turkey -- Kerpeten, A., Kütahya State Hospital, Cardiology Clinic, Kütahya, Turkey -- Delice, A., Kizilay Health Center, Cardiology Polyclinic, Kayseri, Turkey -- Içli, A., Konya Municipality Hospital, Cardiology Clinic, Konya, Turkey -- Sökmen, A., Sütçü Imam University Medical Faculty, Department of Cardiology, Kahramanmaraş, Turkey -- Gürlek, A., Ankara University Medical Faculty, Department of Cardiology, Ibn-i Sina Hospital, Ankara, Turkey -- Abaci, A., Gazi University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Bayram, A., Erzurum Numune State Hospital, Cardiology Clinic, Erzurum, Turkey -- Köşüş, A., Ordu Medical Center, 19 Eylül Internal Diseases Polyclinic, Ordu, Turkey -- Çamsari, A., Mersin University Medical Faculty, Department of Cardiology, Mersin, Turkey -- Sakalli, A., Afyon State Hospital, Cardiology Clinic, Afyon, Turkey -- Sert, A., Beypazari State Hospital, Cardiology Clinic, Ankara, Turkey -- Temizhan, A., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Yilmaz, A., Cumhuriyet University Medical Faculty, Department of Cardiology, Sivas, Turkey -- Daver, A., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Aydinlar, A., Uluda? University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Ergin, A., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Kiliço?lu, A.E., Elazi? State Hospital, Cardiology Clinic, Elazi?, Turkey -- Birdane, A., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Aribaş, A., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Lazo?lu, A., Intermed Medical Center, Cardiology Clinic, Alanya, Antalya, Turkey -- Özdemir, A., 1 Eylül State Hospital, Cardiology Clinic, Uşak, Turkey -- Fiskeci, A., Balikesir State Hospital, Cardiology Clinic, Balikesir, Turkey -- Çelik, A., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Bitigen, A., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Keskin, A., Akhisar State Hospital, Cardiology Clinic, Manisa, Turkey -- Yavuz, A., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Akyüz, A., Sultan 1. Izzettin Keykavuş State Hospital, Cardiology Clinic, Sivas, Turkey -- Karanfil, A., Fatih University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Ünsal, A., Gölcük State Hospital, Cardiology Clinic, Kocaeli, Turkey -- Sinci, A., Bilecik State Hospital, Cardiology Clinic, Bilecik, Turkey -- Gülmez, A.U., Pamukkale State Hospital, Cardiology Clinic, Denizli, Turkey -- Irmak, A., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Vural, A., Toros State Hospital, Cardiology Clinic, Mersin, Turkey -- Güven, A., Sütçü Imam University Medical Faculty, Department of Cardiology, Kahramanmaraş, Turkey -- Ilerigelen, B., Istanbul University Cerrahpaşa Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Erol, B., Giresun State Hospital, Cardiology Clinic, Giresun, Turkey -- Polat, B., Polatli Duatepe State Hospital, Cardiology Clinic, Ankara, Turkey -- Tosun, B., Aydin 82. Yil State Hospital, Cardiology Clinic, Aydin, Turkey -- A?çal, C., Isparta State Hospital, Cardiology Clinic, Isparta, Turkey -- Genç, C., Gülhane Military Medical Academy, Department of Cardiology, Ankara, Turkey -- Kirdar, C., Eskişehir State Hospital, Cardiology Clinic, Eskişehir, Turkey -- Rezzagil, C., Şevket Yilmaz State Hospital, Cardiology Clinic, Bursa, Turkey -- Köz, C., Gülhane Military Medical Academy, Department of Cardiology, Ankara, Turkey -- Nazli, C., Atatürk Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Ceyhan, C., Adnan Menderes University Medical Faculty, Department of Cardiology, Aydin, Turkey -- Örem, C., Karadeniz Technical University Medical Faculty, Department of Cardiology, Trabzon, Turkey -- Uyan, C., Abant Izzet Baysal University Medical Faculty, Department of Cardiology, Bolu, Turkey -- Türko?lu, C., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Gaffari, D., Kizilay Health Center, Cardiology Polyclinic, Üsküdar, Istanbul, Turkey -- Aytekin, D., Salihli Public Hospital, Cardiology Clinic, Manisa, Turkey -- Ural, D., Kocaeli University Medical Faculty, Department of Cardiology, Kocaeli, Turkey -- Yeşilbursa, D., Uluda? University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Aras, D., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Semiz, E., Pamukkale University Medical Faculty, Department of Cardiology, Denizli, Turkey -- Koçak, E., Evliya Çelebi State Hospital, Cardiology Clinic, Kütahya, Turkey -- Atalar, E., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Varol, E., Süleyman Demirel University Medical Faculty, Department of Cardiology, Isparta, Turkey -- Onrat, E., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Şensoy, E., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Acartürk, E., Çukurova University Medical Faculty, Department of Cardiology, Adana, Turkey -- Akarca, E., Nazilli State Hospital, Cardiology Clinic, Aydin, Turkey -- Aygün, E., Bafra State Hospital, Cardiology Clinic, Samsun, Turkey -- Ertaş, F.S., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Koca, F., Alsancak State Hospital, Cardiology Clinic, Izmir, Turkey -- Özmen, F., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Ulusoy, F.V., Ankara Numune Hospital, 2nd Cardiology Clinic, Ankara, Turkey -- Özerkan, F., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Inceer, F.K., Çorum State Hospital, Cardiology Clinic, Çorum, Turkey -- Dönmez, G., Bakirköy Dr. Sadi Konuk Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Topkara, G., Bandirma State Hospital, Cardiology Clinic, Balikesir, Turkey -- Daş, G., 82. Yil State Hospital, Cardiology Clinic, Adiyaman, Turkey -- Bozkurt, H., Antakya State Hospital, Cardiology Clinic, Antakya, Turkey -- Kültürsay, H., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Tikiz, H., Celal Bayar University Medical Faculty, Department of Cardiology, Manisa, Turkey -- Akgöz, H., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Kaymak, H., Tarsus State Hospital, Cardiology Clinic, Mersin, Turkey -- Öney, H., Artvin State Hospital, Cardiology Clinic, Artvin, Turkey -- Ye?in, H., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Bo?a, H., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Gök, H., Selçuk State Hospital, Cardiology Clinic, Izmir, Turkey -- Vural, H., Vedat Ali Özkan State Hospital, Cardiology Clinic, Kayseri, Turkey -- Atasever, H., Adapazari State Hospital, Cardiology Clinic, Adapazari, Turkey -- Arinç, H., Izzet Baysal University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Bozdemir, H., Buca Seyfi Demirsoy State Hospital, Cardiology Clinic, Izmir, Turkey -- Gündüz, H., Izzet Baysal University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Tunar, H., Salihli State Hospital, Cardiology Clinic, Manisa, Turkey -- Atmaca, H., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Do?ru, I., Çukurova State Hospital, Cardiology Clinic, Adana, Turkey -- Özdo?ru, I., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Susal, I., Karşiyaka State Hospital, Cardiology Clinic, Izmir, Turkey -- Kurt, I.T., Atakalp Heart Hospital, Cardiology Clinic, Izmir, Turkey -- Dinçer, I., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Biyik, I., Uşak State Hospital, Cardiology Clinic, Uşak, Turkey -- Tando?an, I., Cumhuriyet University Medical Faculty, Department of Cardiology, Sivas, Turkey -- Jordan, J., Uluda? University Medical Faculty, Department of Cardiology, Bursa, Turkey -- Kulan, K., Trabzon Numune State Hospital, Cardiology Clinic, Trabzon, Turkey -- Şahna, K., Ordu State Hospital, Cardiology Clinic, Ordu, Turkey -- Öztaş, K., Samsun State Hospital, Cardiology Clinic, Samsun, Turkey -- Dönmez, K., Manavgat State Hospital, Cardiology Clinic, Antalya, Turkey -- Övünç, K., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Kaya, K., Bursa State Hospital, Cardiology Clinic, Bursa, Turkey -- Aytemir, K., Hacettepe University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Özdemir, K., Selçuk University Medical Faculty, Department of Cardiology, Konya, Turkey -- Tigen, K., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Saraç, L., Istinye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Sirkeci, M.T., Kizilay Health Center, Cardiology Polyclinic, Erzincan, Turkey -- Çakmak, M., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Şahin, M., Ondokuz Mayis University Medical Faculty, Department of Cardiology, Samsun, Turkey -- Kutlu, M., Harput State Hospital, Cardiology Clinic, Elazi?, Turkey -- Bilge, M., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Bostan, M., Rize State Hospital, Cardiology Clinic, Rize, Turkey -- Melek, M., Afyon Kocatepe University Medical Faculty, Department of Cardiology, Afyon, Turkey -- Sunay, M.Ö., Balikesir State Hospital, Cardiology Clinic, Balikesir, Turkey -- Şeker, M., Meram State Hospital, Cardiology Clinic, Konya, Turkey -- Güçel, M.Ş., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Yazici, M., Düzce University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Kayikçio?lu, M., Ege University Medical Faculty, Department of Cardiology, Izmir, Turkey -- Öç, M., Ümraniye State Hospital, Cardiology Clinic, Istanbul, Turkey -- Gürsürer, M., Karaelmas University Medical Faculty, Department of Cardiology, Zonguldak, Turkey -- Da?alp, M., Ziraat Bank Hospital, Cardiology Clinic, Ankara, Turkey -- Bilalo?lu, M., Erzurum Numune State Hospital, Cardiology Clinic, Erzurum, Turkey -- Yalçin, M., GATA Haydarpaşa Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Şerifi, M., Izmit State Hospital, Cardiology Clinic, Kocaeli, Turkey -- Gökçe, M., Karadeniz Technical University Medical Faculty, Department of Cardiology, Trabzon, Turkey -- Kiliçkap, M., Ankara University Medical Faculty, Department of Cardiology, Heart Center, Ankara, Turkey -- Polat, M., Ceyhan State Hospital, Cardiology Clinic, Adana, Turkey -- Şan, M., Çukurova University Medical Faculty, Department of Cardiology, Adana, Turkey -- Tahtasiz, M., Eşrefpaşa Municipality Hospital, Cardiology Clinic, Izmir, Turkey -- Yilmaz, M., Kayseri State Hospital, Cardiology Clinic, Kayseri, Turkey -- Etemo?lu, M., Izmir Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Coşkun, N., Harput State Hospital, Cardiology Clinic, Elazi?, Turkey -- Aran, N.S., Istanbul University Cerrahpaşa Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Ata, N., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Sönmez, N., Bodrum State Hospital, Cardiology Clinic, Mu?la, Turkey -- Çam, N., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Koylan, N., Istanbul University Istanbul Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Özer, N., Iskenderun State Hospital, Cardiology Clinic, Hatay, Turkey -- Keser, N., Maltepe University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Döven, O., Mersin University Medical Faculty, Department of Cardiology, Mersin, Turkey -- Tartano?lu, O., Karaman State Hospital, Cardiology Clinic, Karaman, Turkey -- Ergene, O., Atatürk Training and Research Hospital, Cardiology Clinic, Izmir, Turkey -- Elönü, O.H., Melikgazi Hospital, Cardiology Clinic, Kayseri, Turkey -- Onbaşili, O.A., Adnan Menderes University Medical Faculty, Department of Cardiology, Aydin, Turkey -- Özbek, Ö., Marmara University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Pinar, P., Manisa State Hospital, Cardiology Clinic, Manisa, Turkey -- Akdemir, R., Düzce University Medical Faculty, Department of Cardiology, Düzce, Turkey -- Kargin, R., Kartal Koşuyolu Training and Research Hospital, Cardiology Clinic, Istanbul, Turkey -- Topsakal, R., Erciyes University Medical Faculty, Department of Cardiology, Kayseri, Turkey -- Yoldaş, R., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Uçar, R., Giresun State Hospital, Cardiology Clinic, Giresun, Turkey -- Ateşal, S., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Toktaş, S., Adana Numune Training and Research Hospital, Fatma Timurçin Heart Center, Adana, Turkey -- Cinsoy, S., Sabuncuo?lu Şerafeddin State Hospital, Cardiology Clinic, Amasya, Turkey -- Güleç, S., Ankara University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Aytekin, S., Kadir Has University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Çolak, S., Kizilay Health Center, Cardiology Polyclinic, Sivas, Turkey -- Mecit, S., Çanakkale Şehitlik State Hospital, Cardiology Clinic, Çanakkale, Turkey -- Sakalli, S., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey -- Sevimli, S., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Topalo?lu, S., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Aydo?du, S., Ankara Numune Hospital, Cardiology Clinic, Ankara, Turkey -- Turan, S.C., Fatih Sultan Mehmet State Hospital, Cardiology Clinic, Istanbul, Turkey -- Kahraman, S., Ni?de State Hospital, Cardiology Clinic, Ni?de, Turkey -- Yorganci, S., Atatürk State Hospital, Cardiology Clinic, Antalya, Turkey -- Coşkun, Ş., Bursa State Hospital, Cardiology Clinic, Bursa, Turkey -- Ünal, Ş., Nevşehir State Hospital, Cardiology Clinic, Nevşehir, Turkey -- Durmaz, T., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Ulusoy, T., Aksaray State Hospital, Cardiology Clinic, Aksaray, Turkey -- Keleş, T., Ankara Atatürk Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Kirat, T., Mu?la State Hospital, Cardiology Clinic, Mu?la, Turkey -- Gündo?du, T.T., Gebze Fatih Hospital, Cardiology Clinic, Kocaeli, Turkey -- Peker, T., Gemlik State Hospital, Cardiology Clinic, Bursa, Turkey -- Sümerkan, U., Marmara University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Aytekin, V., Kadir Has University Medical Faculty, Department of Cardiology, Istanbul, Turkey -- Koca, V., Bursa Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Bursa, Turkey -- Çam, V., Fethiye State Hospital, Cardiology Clinic, Mu?la, Turkey -- Gökçe, V., Konya Numune State Hospital, Cardiology Clinic, Konya, Turkey -- Gürlertop, Y., Atatürk University Medical Faculty, Department of Cardiology, Erzurum, Turkey -- Balbay, Y., Ankara Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Çavuşo?lu, Y., Osmangazi University Medical Faculty, Department of Cardiology, Eskişehir, Turkey -- Erzurum, Y., Eskişehir Yunus Emre State Hospital, Cardiology Clinic, Eskişehir, Turkey -- Selçoki, Y., Fatih University Medical Faculty, Department of Cardiology, Ankara, Turkey -- Yakar, Y., Tokat State Hospital, Cardiology Clinic, Tokat, Turkey -- Işilak, Z., GATA Haydarpaşa Training and Research Hospital, Department of Cardiology, Istanbul, Turkey -- Tosun, Z., Antalya State Hospital, Cardiology Clinic, Antalya, Turkey -- Kaplan, Z., Ankara Training and Research Hospital, Cardiology Clinic, Ankara, Turkey -- Tartan, Z., Siyami Ersek Hospital, Cardiology Clinic, Istanbul, Turkey, Maltepe Üniversitesi, and Çukurova Üniversitesi

Subjects
Male, heart atrium fibrillation, Turkey, Cross-sectional study, urinalysis, anticoagulant agent, Coronary artery disease, Turkey (republic), hydroxymethylglutaryl coenzyme A reductase inhibitor, low density lipoprotein cholesterol, sedentary lifestyle, Risk Factors, high density lipoprotein cholesterol, cardiovascular disease, middle aged, dipeptidyl carboxypeptidase inhibitor, Albuminuria/complications/epidemiology, Cardiovascular diseases, Hypertension/complications, Prevalence, Risk factors, Turkey/epidemiology, Medicine, Family history, family history, education.field_of_study, C reactive protein, adult, creatinine, article, beta adrenergic receptor blocking agent, clinical trial, antithrombocytic agent, Middle Aged, urine, comorbidity, ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS, female, congestive heart failure, risk factor, laboratory test, diabetes mellitus, Hypertension, antihypertensive agent, Female, triacylglycerol, InformationSystems_MISCELLANEOUS, Cardiology and Cardiovascular Medicine, cardiovascular risk, Adult, disease control, medicine.medical_specialty, microalbuminuria, heart infarction, Population, Urinalysis, albuminuria, smoking, Young Adult, blood, Internal medicine, cross-sectional study, Albuminuria, Humans, human, Risk factor, Intensive care medicine, education, Triglycerides, concentration (parameters), business.industry, screening, dyslipidemia, Cholesterol, HDL, ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS, cholesterol, Cholesterol, LDL, medicine.disease, major clinical study, Comorbidity, brain ischemia, predictor variable, multicenter study, Cross-Sectional Studies, ComputingMethodologies_PATTERNRECOGNITION, transient ischemic attack, observational study, Microalbuminuria, disease duration, business, Dyslipidemia, peripheral occlusive artery disease
Abstract

PubMed ID: 22257801, Objectives: A growing body of data illustrates the importance of microalbuminuria (MAU) as a strong predictor of cardiovascular risk in the hypertensive population. The present study was designed to define the prevalence of MAU and associated cardiovascular risk factors among Turkish hypertensive outpatients. Study design: Representing the Turkish arm of the multinational i-SEARCH study involving 1,750 sites in 26 countries around the world, a total of 1,926 hypertensive patients from different centers were included in this observational and cross-sectional survey study. Patients with reasons for a false-positive MAU test were excluded. The prevalence of MAU was assessed using a dipstick test, and patients were inquired about comorbidities, comedication, and known cardiovascular risk factors. Results: The overall prevalence of MAU was 64.7% and there was no difference between genders. Most of the patients (82.5%) had uncontrolled hypertension, 35.6% had dyslipidemia, and 35.5% had diabetes, predominantly type 2. Almost one-third of the patients (26.4%) had at least one cardiovascular-related comorbidity, with 20.3% having documented coronary artery disease (CAD). Almost all patients (96.8%) had one or more risk factors for cardiovascular disease in addition to hypertension, including family history of myocardial infarction or CAD, diabetes, dyslipidemia, lack of physical exercise, and smoking. A trend towards higher MAU values in the presence of CAD was determined. Conclusion: Microalbuminuria tests should be routinely used as a screening and monitoring tool for the assessment of subsequent cardiovascular morbidity and mortality among hypertensive patients. © 2011 Turkish Society of Cardiology.

Published
2011

32. Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

Author

Metin Isik, Dogan Uncu, Hatice Odabas, Mehmet Metin Seker, Fahriye Tugba Kos, and Nurullah Zengin

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Gastroenterology, Deoxycytidine, Disease-Free Survival, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, Progression-free survival, Aged, Retrospective Studies, Chemotherapy, business.industry, Cancer, Hematology, General Medicine, Middle Aged, medicine.disease, Gemcitabine, Surgery, Squamous carcinoma, Oncology, Adenocarcinoma, Neoplasms, Unknown Primary, Female, Cisplatin, business, Progressive disease, medicine.drug
Abstract

The optimal therapy for carcinoma of unknown primary site (CUPS) is still under investigation. In this retrospective trial, we reported the response rates and overall and progression free survival of 23 CUPS patients that were treated with gemcitabine and cisplatin. The mean age of the patients was 54.95 (32–77). Sixteen (69.6%) of them were males and 7(30.4%) females. Totally 109 cycles with a mean of 6 were administered. Thirteen of 23 patients (56.5%) presented with only one metastatic site, and the liver is the most frequent metastatic site (39.1%). Histologic types were adenocarcinoma in 14 patients (60.8%), squamous carcinoma in 1 patient (4.8%), epithelioid cancer in 3 patients (13%) and undifferentiated cancer in 5 patients (21.7%). Three patient achieved a CR (13%), 4 patients achieved a PR (17.4%) and 8 patients had SD (34.8%) with an overall 30.4% response rate. However, 8 patients had progressive disease with a percentage of 34.8%. The median follow-up time was 10 months (3–42 months). The mean and median survival was 12.5 (3–42) months and 10 months (range, 3–42 months) and progression free survival was 5.5 months (range, 0–23 months). Gemcitabine plus cisplatin may be an effective treatment of CUPS. Therefore additional trials are needed especially with new chemotherapeutics.

Published
2009

33. The diagnostic and prognostic value of UHRF-1 and p53 in gastric cancer

Author

Nalan Akgul Babacan, Sener Cihan, Birsen Yücel, Ilknur Parlak, Reyhan Egilmez, Aykut Bahceci, Bulent Akinci, Mehmet Metin Seker, Saadettin Kilickap, Turgut Kaçan, and Cumhuriyet Univ, Dept Med Oncol, Sivas, Turkey -- Cumhuriyet Univ, Dept Pathol, Sivas, Turkey -- Cumhuriyet Univ, Dept Radiat Oncol, Sivas, Turkey -- Cumhuriyet Univ, Fac Med, Dept Med Oncol, Sivas, Turkey -- Cumhuriyet Univ, Dept Internal Med, Sivas, Turkey -- Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey -- Yildirim Beyazit Univ, Dept Med Oncol, Ankara, Turkey -- Hacettepe Univ, Inst Canc, Ankara, Turkey

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Tumor suppressor gene, business.industry, Cancer, medicine.disease, Gastroenterology, Internal medicine, medicine, Over expression, Immunohistochemistry, Gastritis, medicine.symptom, business, Cancer death
Abstract

50th Annual Meeting of the American-Society-of-Clinical-Oncology -- MAY 30-JUN 03, 2014 -- Chicago, IL, WOS: 000358613200488, …, Amer Soc Clin Oncol

Published
2014
Full Text
View/download PDF

34. The negative prognostic impact of bone metastasis with a tumor mass

Author

Birsen Yücel, Mustafa Gürol Celasun, Bilge Öztoprak, Zekiye Hasbek, Seher Bahar, Turgut Kaçan, Aykut Bahçeci, and Mehmet Metin Şeker

Subjects
Bone metastasis, Bone metastasis with a tumor mass, Prognostic factor, Survival, Medicine (General), R5-920
Abstract

OBJECTIVE:Typically, bone metastasis causes osteolytic and osteoblastic lesions resulting from the interactions of tumor cells with osteoclasts and osteoblasts. In addition to these interactions, tumor tissues may grow inside bones and cause mass lesions. In the present study, we aimed to demonstrate the negative impact of a tumor mass in a large cohort of patients with bone metastatic cancer.METHODS:Data from 335 patients with bone metastases were retrospectively reviewed. For the analysis, all patients were divided into three subgroups with respect to the type of bone metastasis: osteolytic, osteoblastic, or mixed. The patients were subsequently categorized as having bone metastasis with or without a tumor mass, and statistically significant differences in median survival and 2-year overall survival were observed between these patients (the median survival and 2-year overall survival were respectively 3 months and 16% in patients with a tumor mass and 11 months and 26% in patients without a tumor mass; p

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results